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1. Introduction 
Cancer is one of the leading causes of morbidity and mortality 
worldwide, causing about 13% of all human deaths and at least 
one fifth of all deaths in Europe and North America.1,2 Classical 
cancer chemotherapy is associated with significant adverse 
effects due to the nature of the treatment: all rapidly dividing 
cells are treated the same leading to the well-known effects of 
myelosuppression, alopecia and many others.  
More recently, targeted therapies have emerged using drugs that 
interfere with specific molecular targets involved in cancer 
progression. One such target is a series of enzymes responsible 
for signal transduction called protein kinases which modify other 
proteins by transferring phosphate groups from a high-energy 
donor molecule, such as adenosine triphosphate (ATP), to a 
specific substrate amino acid on the target protein. This 
phosphorylation results in a conformational change in the 
protein, affecting its function in areas such as enzyme activity, 
association with other proteins or cellular location.3 In this way 
kinases regulate other proteins and the activities of cells, playing 
an important role in many intracellular signalling pathways 
including those that control cell growth and cell division. This 
role in cell signalling, makes them an object of study for drug 
design.4,5 
Deregulated kinase activity has been implicated in a variety of 
human health conditions including disorders of the immune 
system, neurodegenerative disorders and diabetes, as well as 
cancer. Since the discovery that staurosporine 1 (Figure 1) was a 
nanomolar inhibitor of PKC in 1986,6 great interest has been 
generated into obtaining highly active and selective protein 
kinase inhibitors either through chemical synthesis or screening 
of new natural products.  
The first kinase inhibitor to be approved by the FDA was 
imatinib 2 in 2001 (Figure 1), as a treatment for chronic myeloid 
leukemia. By April 2015, a total of 28 small-molecule kinase 
inhibitors have been approved for clinical use by the FDA, half 
of which were approved in the past 3 years.7 These include 
erlotinib 3, which is marketed as a treatment for non-small cell 
lung cancer, and sunitinib 4, which is marketed as a treatment for 
renal cell carcinoma and imatinib-resistant gastrointestinal 
stromal tumour.8,9 A large number are also currently undergoing 
human clinical trials for cancer and other conditions. 
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Synthesis and biological evaluation of a series of novel indole derivatives as anticancer agents is 
described. A bisindolylmaleimide template has been derived as a versatile pharmacophore with 
which to pursue chemical diversification. Starting from maleimide, the introduction of an 
oxygen to the headgroup (hydroxymaleimide) was initially investigated and the bioactivity 
assessed by screening of kinase inhibitory activity, identifying substituent derived selectivity. 
Extension of the hydroxymaleimide template to incorporate substitution of the indole nitrogens 
was next completed and assessed again by kinase inhibition identifying unique selectivity 
patterns with respect to GSK-3 and CDK kinases. Subsequently, the anticancer activity of 
bisindolylmaleimides were assessed using the NCI-60 cell screen, disclosing the discovery of 
growth inhibitory profiles towards a number of cell lines, such as SNB-75 CNS cancer, A498 
and UO-31 renal, MDA MB435 melanoma and a panel of leukemia cell lines. The potential for 
selective kinase inhibition by modulation of this template is evident and will inform future 
selective clinical candidates. 
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Figure 1 Structures of common kinase inhibitors 1-4  
Many biologically relevant kinase inhibitors, including 
staurosporine 1, have been shown to work by competing with 
ATP.10-12 The interaction of staurosporine with the ATP-binding 
site has been proven through the resolution of crystal structures 
of staurosporine bound to CDK2 and PKA. These crystal 
structures show the indolocarbazole derivative being located in 
the ATP binding site, in the cleft between the two lobes of the 
protein kinase. The lactam/maleimide group mimics the 
hydrogen bonding pattern of the adenine base of ATP by forming 
two hydrogen bonds to the backbone of the hinge between the N-
terminal and C-terminal domains of the kinase. The sugar moiety 
then forms hydrogen bonds within the ribose binding site. Due to 
the similarity between ATP binding sites in different kinases, 
staurosporine is a highly potent but unspecific kinase inhibitor. 
However, by structural modification it has been possible to 
obtain some selectivity by exploiting differences in the mode of 
ligand interaction in the ATP-binding pocket.13 
Removal of the central ring leads to a group of compounds called 
the bisindolylmaleimides. Due to their increased conformational 
flexibility, the binding mode of bisindolylmaleimides is more 
complex than that of staurosporine.14 Initially, GF 109203 X 5 
and Ro 318220 6 (Figure 2) were reported to be potent and 
selective inhibitors of protein kinase C (IC50 = 10 nM and 20 nM, 
respectively).15,16 However, they were later found to also potently 
inhibit several other kinases, such as MAPKAP kinase-1β (IC50 = 
50 nM and 3 nM, respectively) and GSK-3β (IC50 = 360 nM and 
6.8 nM, respectively).17,18 
Another analogue, ruboxistaurin 7 (Figure 2), has been reported 
to be a specific inhibitor of the PKC isoforms, PKCβ1 (IC50 = 4.7 
nM) and PKCβ2 (IC50 = 5.9 nM).19 It displays selectivity over 
other protein kinases and PKC isoforms such as PKCα (IC50 = 
360 nM), PKCγ (IC50 = 300 nM), PKCε (IC50 = 600 nM) and 
PDK1 (IC50 = 750 nM) but has since been identified with PIM 
kinase inhibition (IC50 = 200 nM).20 Ruboxistaurin entered 
clinical trials for the treatment of diabetic peripheral retinopathy. 
Enzastaurin 8 (Figure 2) is a highly potent inhibitor of PKCβ 
(IC50 = 6 nM) and the PI3K/Akt pathway.21 It shows moderate 
selectivity over other PKC isoforms including PKCα (IC50 = 39 
nM), PKCγ (IC50 = 83 nM) and PKCε (IC50 = 110 nM). 
Enzastaurin also underwent clinical trials for cancers such as 
glioblastoma, non-small cell lung cancer and colorectal cancer.  
Kuo et al. also investigated the synthesis of a panel of novel 
indole substituted bisindolylmaleimide derivatives which were 
found to be potent inhibitors of GSK-3β (Figure 3).22 
Figure 2 The bisindolylmaleimide class of kinase inhibitors 5-8 
Although the bisindolyl analogue 9a was highly active against 
GSK-3β (IC50 = 22 nM), it was not specific and was also active 
against several other kinases such as CDK1 and CDK2, VEGF-R 
and several PKC isoforms. Replacing one of the indole rings with 
7-azaindole (compound 9b) had little effect on the potency or 
selectivity at GSK-3β (IC50 = 17 nM) but the replacement of both 
indoles with 7-azaindole (compound 9c) significantly increased 
the selectivity. The bis-7-azaindolylmaleimide 9c showed limited 
activity against a panel of 50 other kinases indicating a specific 
inhibitor of GSK-3β (IC50 = 34 nM). Subsequent extension of this 
replacing one of the azaindoles with other aryl substituents 
yielded good potency but were compromised by CDK2/5 activity 
in a full kinase screen.23,24  
Figure 3 Azaindole/indole bisindolylmaleimides with selectivity 
of kinase inhibition  
It is therefore evident that indole substitution and azaindole 
incorporation can affect potent kinase inhibition of this 
pharmacophore. However, one key unexplored area in the SAR is 
the headgroup maleimide. We hereby describe the discreet 
exploration of this space via simple conversion to 
hydroxymaleimide coupled with novel indole substituents to 
probe the relationship of steric bulk on kinase binding and 
selectivity using a scope of kinase inhibition and cellular growth. 
A panel of 10 serine/threonine kinases was selected for initial 
assay to complement screening via the NCI 60 cell line screen for 
cancer cell growth.  
2. Results and Discussion 
2.1 Synthesis of azaindole indole maleimide and 
hydroxymaleimide 
Our initial approach envisaged a bisindolylmaleimide and 
corresponding bisindolylhydroxymaleimide in order to probe 
whether atomic incorporation would differentiate activity and our 
starting point incorporated an indole, 7-azaindole and maleimide 







































































































bisindolylmaleimides, it is surprising that the hydroxymaleimide 
model has very little precedent. To date there exist only three 
reported compounds with this substructure and none when a 7-
azaindole is incorporated (although it is more common for 
indolocarbazoles).25 Hence this is a field ripe for discovery 
especially since the reported compounds possess bioactivity 
(micromolar PKC and PKA inhibition).  
The application of Perkin-type condensation methodology 
towards the synthesis of novel maleic anhydride 14 proved to be 
relatively straightforward (Scheme 1). Initially, N-methylindole-
3-acetic acid 13 was formed by alkylation of indole-3-acetic acid 
12, with acid 13 formed in 84% yield.26 Separately, a stirred 
solution of N-methyl-7-azaindole 10 was treated with oxalyl 
chloride and corresponding glyoxyl chloride 11 was isolated as 
an off-white solid in quantitative yield. Glyoxyl chloride 11 was 
then added to a stirred solution containing N-methylindole-3-
acetic acid 13 and triethylamine in DCM, with isolation of maleic 
anhydride 14 as a bright red solid in 37% yield achieved by flash 
column chromatography (Scheme 1). Conversion of maleic 
anhydride 14 to maleimide 15 occurred in excellent yield of 88% 
via treatment with hexamethyldisilazane. Hence, compound 15 










































Scheme 1 Synthesis of maleimide 15 via Perkin-type 
condensation 
Synthesis of a related hydroxymaleimide was undertaken in order 
to probe the effect of oxygen insertion into the headgroup and the 
effect of indole substitution (Scheme 2). 7-Azaindole 16 was 
converted to the ethyl glyoxylate 17 followed by hydrolysis to 
the glyoxylate salt 18. Perkin condensation of this with 
benzenesulfonyl protected indole-3-acetic acid 19 yielded the 
protected maleic anhydride 20.26 This was subsequently 
deprotected and converted to the hydroxymaleimide 22 via 
treatment with hydroxylamine. 
2.2 Evaluation of the kinase inhibitory activity of lead 
compounds 15 and 22 
Due to the common reports of bisindolylmaleimides as kinase 
inhibitors and the reported polypharmacology of the class, as 
discussed in the introduction, the standard maleimide 15 and 
novel hydroxymaleimide 22 were evaluated by a preliminary 












































Scheme 2 Synthesis of maleimide 22 via Perkin-type condensation 
GSK-3β has been shown to reduce apoptosis signals it may be 
useful for the treatment of Alzheimer’s disease and protection 
against cell death.29,30 In addition to the data above, there are 
reports of bisindolylmaleimide involvement with GSK-3β in the 
regulation of murine embryonic stem cell self-renewal so it is an 
obvious starting point.27 Interestingly, inhibitors of GSK-3 have 
also been shown to enhance apoptotic signal transduction 
induced by TRAIL (TNF-related apoptosis inducing ligand 
TRAIL).31 
The evaluation of derivatives for their inhibition of cancer-related 
protein kinases is also of relevance: HsHaspin, HsAurora kinase 
B, HsRIPK3, HsCDK2, HsCDK5, HsCDK9, RnDYRK1A, 
HsPIM1 and SscCK1δ/ε. Haspin is expressed in a variety of 
tissues (e.g., testis, bone narrow, thymus, and spleen) and in 
proliferating cells, including in a number of neoplasms.32,33,34 
Aurora-B is a key component of the spindle assembly checkpoint 
and also functions in cytokinesis.35 The receptor-interacting 
protein kinase-3 (RIPK3 or RIP3) is a critical regulator of 
necroptosis.36-38 A recent study showed the important role of 
RIPK3 in maintaining in vivo tumor growth with RIPK3 
knockout breast tumor cell growing at a significantly slower rate 
than vector control cells.39 The Cyclin-Dependant Kinases 
(CDKs) play a direct role in the regulation of the cell cycle 
controlling cell proliferation. CDK2 has been shown to have a 
direct role in the cell cycle progression, while CDK subtypes 7–9 
have been described to control RNA polymerase II mediated 
transcription and CDK5 is involved in neuronal function.40 Dual-
specificity tyrosine phosphorylation-regulated kinase 1A 
(DYRK1A)41 is involved in many major diseases, including 
cancer and neurodegenerative disorders.41-43 PIM1 is a 
constitutively active enzyme and has been shown to have diverse 
biological roles in cell survival, proliferation, differentiation and 
apoptosis.44 Overexpression of PIM-1 has been found in various 
hematopoietic malignancies as well as in solid tumors including 
colon, prostate and pancreas.45 CK1 (casein kinase 1), when 
deregulated, is responsible for non-regulation of growth, 
proliferation, and apoptosis which may result in pathological 
conditions, such as tumorigenesis or neurological diseases.46  
Results from one dose assay at 10 µM concentration confirmed 
that the maleimide was significantly more active than the 
hydroxymaleimide (see Table 1, Supporting Information). 
Significant kinase inhibition was seen for the maleimide 15 in all 
the CDKs (CDK2, CDK5 and CDK9) in addition to GSK-3 and 
PIM1 kinases. By contrast, the introduction of an oxygen into the 
headgroup and removal of the indole methyl substituents reduced 
the CDK activity completely with significant kinase inhibition 
only evident in PIM1 kinase and to a lesser extent in CK1 and 
GSK-3. This intriguing disparity and potential selectivity led to 
an exploration of the molecular space occupied by the headgroup 
and the indole substituents. 
2.3 Synthesis of novel bisindolylmaleic anhydrides with 
symmetrical N-substituents 
At the outset we decided to base our study on the novel 
bisindolylhydroxymaleimide series as this would probe the 
indole substituent effects without any competing/conflicting 
effects from the nitrogen of 7-azaindole. Initial synthesis begins 
from indole which is converted to the potassium salt of indole-3-
glyoxylic acid 23 in excellent yield (Scheme 3).47 After a 
deprotonation step, subsequent Perkin condensation in the 
presence of acetic anhydride with benzenesulfonyl protected 
indole-3-acetic acid 19 renders the fully protected maleic 
anhydride 25 in moderate yield. Complete hydrolysis can be 
achieved with aqueous base allowing for derivatisation of both 
indole nitrogens simultaneously.48 To this end, the novel hexane 
bisindolyl maleic anhydride 27 was generated as a test 
macrocycle. Reaction of the same unsubstituted 26 with 6-
bromohexanenitrile yielded both the mono- and bis-substituted 
hexanenitrile anhydrides 28 and 29. Hydrolysis of 29 yields the 












































































Scheme 3 Synthesis of key maleic anhydrides 27-30   
2.4 Synthesis of novel bisindolyl maleic anhydrides with 
unsymmetrical N-substituents 
In order to probe the influence of indole nitrogen substitution on 
the anticancer and kinase activity of these compounds a synthetic 
route was devised to incorporate individual functionality on the 
indoles (Scheme 4). To achieve selective substitution of either 
nitrogen the strategy was adapted to incorporate an alkylation of 
the indole at an earlier stage and this was brought through a 
similar sequence. 1-Methyl (in order to correspond to 15) and 1-
isopropyl (to probe steric bulk) indole 31-32, were generated 
from the starting indole and the corresponding potassium 
glyoxylate salts 35-36 were generated as above. These undergo 
Perkin condensation in the presence of acetic anhydride and 
indole acetic acid 19, and subsequent base mediated deprotection 
yielding the mono-alkylated bisindolyl maleic anhydrides 39-
40.49 These are then available for further alkylation to form fully 
functionalised maleic anhydrides (Scheme 5 or in the case of 44 
base hydrolysis) to form anhydrides 41-46. From observation of 
the 1H NMR data, there is an interesting correlation between the 
substitution on the indole nitrogen and the chemical shift values 















1. NaH, DMF, 0°C, 30 min

























31: R1 = Me, 95%
32: R1 = iPr, 59% 33
: R1 = Me, 74%
34: R1
 = iPr, 90%
35: R1
 = Me, 95%
36: R1
 = iPr, 97%37: R1
 = Me, 31%
38: R1
 = iPr, 24%
39: R1 = Me, 95%
40: R1 = iPr, 87%
19
Scheme 4 Synthesis of maleic anhydrides 39-40   
2.5 Synthesis of novel bisindolylhydroxymaleimides 
Formation of the ultimate hydroxymaleimides 47-58 was 
achieved by condensation with hydroxylamine hydrochloride salt 
in the presence of trimethylamine and yields were generally 












1. NaH, DMF, rt, 40 min






Scheme 5 Synthesis of hydroxymaleimides 47-58 via novel 
maleic anhydrides 27, 28, 30, 39-46 
Table 1 Structure and synthetic yields of 41-58 via alkylation (A) 






R1 R2 Yield (A) 
Yield 
(B) 
47 39 Me H - 83% 
48 39 Me Me 80% (41) 84% 
49 39 Me Et 72% (42) 69% 
50 39 Me (CH2)5CN  
40% 
(43) 82% 
51 43 Me (CH2)5COOH 
76% 
(44)* 79% 
52 40 iPr H - 77% 
53 40 iPr Me 46% (45) 93% 
54 40 iPr Et 51% (46) 80% 
55 27 -CH2(CH2)4CH2- - 82% 
56 28 (CH2)5CN (CH2)5CN - 87% 
57 30 (CH2)5COOH  H - 86% 
58 28 (CH2)5CN (CH2)5CN - 90%** 
* Using the method as per the formation of 30 in Scheme 3; ** 
Using HMDS rather than hydroxylamine form the corresponding 
maleimide for reference purposes. 
2.6 Kinase screen 
The full library of novel substituted bisindolylmaleimides was 
initially probed for kinase inhibitory activity against 10 kinase 
enzymes at a concentration of 10 µM (see Table 1, Supporting 
Information). It is very evident that small changes in the 
substitution pattern affect the ability to modulate phosphorylation 
in a discreet fashion. As mentioned above, there is a striking 
difference in the activity of related bisindolylmaleimides 15 and 
22 and again it is evident that extension of the pharmacophore at 
the indole nitrogens influences inhibition. From the heat map it 
can be seen that CDK9, GSK-3 and, to a lesser extent, PIM1 
kinase are all substantially affected by the panel, aside from 55 
which is interesting given that it is the macrocyclic 
bisindolylmaleimide. This suggests that restricting the 
conformation in this way reduces the kinase activity (in contrast 
to the known kinase inhibitor ruboxistaurin 7, see Figure 2). It is 
also seen that 51 and 53 have a similar profile to 15. 
2.7 Kinase assay 
Given the excellent selectivity and potency evident in the kinase 
screen, the full library of novel substituted bisindolylmaleimides 
progressed to kinase inhibitory assay (Table 2).50 The most potent 
compound of the panel was the lead maleimide 15 with activity 
against GSK-3 30 nM, CDK2/5/9 80-800 nM and PIM1 2 µM. 
On evaluating GSK-3 inhibition, the hydroxymaleimides are 
active irrespective of indole substituent (save for the inactive 
macrocyclic 55) which suggests a mode of binding for this 
template whereby incorporation of anchoring subunits on the 
indole nitrogens (as in 5, 6 and 8, Figure 2) may be fruitful.  
The removal of indole substitution and incorporation of the 
hydroxymaleimide headgroup rendered GSK-3 and PIM1 
selective inhibition albeit at 4-4.5 µM (15 vs 22). Comparing 47 
and 48 which differ in only by the presence of a methyl 
substituent, the influence of the indole N-H gives rise to more 
potency against GSK-3 (200 nM). However this effect is not a 
constant as on extension of the alkyl substituent further potency 
is seen for 49, 50, 53 and 54 showing the positive influence of at 
least one bulky substituent. Interestingly 51 and 54 have 
submicromolar inhibition of CDK-9 kinase which could be 
exploited as a cancer target.51 
In comparing the methyl against the propyl subsets (47-49 Vs 52-
54) it is evident that the increased steric bulk of the propyl 
substituent is tolerated by GSK-3. Extending the alkyl chain 
further to hexanenitrile 50, maintains potency against GSK-3 and 
kinase selectivity over CDKs. Conversion of 50 to carboxylic 
acid 51 improves the potency to CDK-9 rather than GSK-3 with 
the introduction of DYRK inhibition while removal of a methyl 
from 51 to yield 57 reverses this effect. Interestingly, the 
bishexanenitrile substitution pattern of 56 imbues selectivity of 
action over CDKs and with inhibition of GSK kinase at 750 nM 
and is a lead for future studies. 
Finally, in order to confirm the selectivity imposed by the N-OH 
group extension of the maleimide, a direct comparison with the 
corresponding maleimide 58 returns the potency with consequent 
polykinase inhibition (GSK, DYRK, CDK-2/9). It is clearly 
evident that the incorporation of the oxygen limits the CDK and 
DYRK inhibition seen with maleimides. 
2.8 Full anticancer evaluation. 
Selected compounds were identified for further studies into their 
effect on cancer cells through the NCI anticancer screening 
programme. Compound 15, 47-48, 50-53, and 55-58 were chosen 
in order to scope the breadth of structural diversity and kinase 
inhibition.52 The compounds were initially screened (again at 10 
µM) in a cellular based assay against the NCI 60-cell line panel 
with some interesting results compared with other headgroups 
(Table 3).53,54 The majority gave high mean growth across the 60 
cell lines at 10 µM (70-100%) but intriguingly the restriction of 
cellular growth appears related to kinase inhibition given the 
potencies seen in Table 3. Specific growth percentages for two 
renal, three melanoma and one leukaemia cell lines are given and 
it is evident that the indole substitution affects activity. 
Evaluation of compound 47 with one methyl N-substituent and 
one unsubstituted indole identified an average mean growth of 
78.0% across all 60 cell lines. Inhibition was observed for 
leukaemia cell lines (growth reduced to 31% in SR) and also for 
melanoma cell line MDA-MB-435 (17%), renal cancer cell line 
UO-31 (41%) and breast cancer cell line MCF7 (31%). Addition 
of a second methyl substituent significantly reduced activity with 
compound 48 being almost completely inactive; although some 
growth inhibition was observed for leukaemia cell line SR (75%), 
melanoma cell line LOX IMVI (73%) and renal cancer cell line 
UO-31 (74%). Compounds with an isopropyl substituent (52 and 
53) were mostly inactive apart from a similar selectivity towards 
LOX IMVI (59% and 62%, respectively) and UO-31 (68% and 
56%, respectively) and for most leukaemia cell lines. Compounds 
with one extended alkyl chain with a nitrile or carboxylic acid 
functional group displayed little activity with nitrile 50 being 
slightly more active than acids 51 and 57. These compounds 
again displayed moderate inhibition of LOX IMVI and UO-31.  
Table 3 Summary of activity of selected bisindolylmaleimides in 






















(762129) 29 -20 -13 13 41 23 12 
47 
(775309) 78 79 76 17 51 41 31 
48 
(774887) 98 86 102 95 73 74 75 
50 
(776694) 91 77 94 68 60 51 67 
51 
(776691) 96 92 - 102 80 63 90 
52 
(775308) 94 94 87 102 59 68 86 
53 
(775307) 91 99 87 104 62 56 - 
55 
(781334) 103 88 120 111 79 80 92 
56* 
(776693) 68 69 68 16 30 44 18 
57 
(776692) 98 89 99 102 80 61 
100 
58 
(781333) 87 54 96 105 70 73 
- 
* Compounds taken forward to five dose assay by NCI. 
Interestingly, addition of a second nitrile chain significantly 
increased activity with compound 56 displaying a mean growth 
of 68% and being selected to progress to five dose  assay. This 
derivative exhibited considerable activity towards a number of 
individual cell lines, including leukaemia cell lines HL-60(TB) 
(15%) and SR (18%), melanoma cell lines LOX IMVI (30%) and 
MDA-MB-435 (16%), renal cancer cell line UO-31 (44%) and 
breast cancer cell lines MCF7 (40%) and MDA-MB-231/ATCC 
(40%). Replacement of the hydroxymaleimide moiety with an 
unsubstituted maleimide surprisingly reduced activity, with 
compound 58 showing a mean growth of 87%. 
The derivative with both indole nitrogens linked by a 6-carbon 
chain 55 was found to be almost completely inactive with a mean 
growth of 103% and little deviation from the mean growth across 
the panel. This was a rather disappointing result as maleimide 
analogue has been reported to inhibit of a number of kinases 
including PKCα (Ki = 0.3 μM), p70 S6K (Ki = 0.9 μM) and 
GSK-3β (Ki = 0.7 μM), and is analogous to ruboxistaurin.19,55  
However, the most active anticancer agent in the screen was 
compound 15 with a mean growth response of just 29%. This 
compound was taken forward to five dose assays (along with 56). 
A summary of the effects of compound 15 on the NCI 60 cell 
line panel identifies that the mean GI50 of the compound is 5 µM 
and that the anticancer effects are not particularly specific for any 
cancer sub-type or cell phenotype (see Supplementary 
Information). It is clearly evident that there is a cytostatic effect 
at concentrations around 10 µM for all cell lines but this does not 
translate into a cytotoxic effect at higher concentrations in the 
majority of cases. Specific cell lines with sub-micromolar growth 
inhibition values include: SNB-75 (GI50 = 291 nM); MDA-MB-
435 (GI50 = 648 nM); A498 (GI50 = 320 nM); HS 578T (GI50 = 
847 nM). From this it can be seen that the spread of activity over 
CNS, Melanoma, Renal and Breast cancer cell lines and the 




Cell line GI50 µM TGI µM LC50 µM 
15 56 15 56 15 56 
Leukaemia HL-
60(TB) 
4.05 2.54 17.9 6.44 >100 >100 
SR 1.04 3.55 18.4 9.48 >100 >100 
Melanoma MDA-
MB-435 
0.648 2.74 19.3 8.31 >100 >100 
SK-
MEL-5 
2.15 2.92 5.80 10.6 21.8 42.8 
UACC-
62 
4.22 3.23 22.0 16.0 96.7 84.4 
CNS SNB-75 0.291 2.84 7.97 20.0 94.6 >100 
Breast HS-578T 0.847 3.97 4.06 >100 >100 >100 
Renal A498 0.320 2.36 2.34 86.0 >100 >100 
Table 4 Selected GI50, TGI and LC50 data for 15 and 56 
Bishexanenitrile derivative 56 had a relatively high mean growth 
on one dose screening but low micromolar GI50 values were 
observed for a number of cell lines, especially in leukaemia and 
melanoma cancer types. It is of interest to note that a number of 
values are lower for 56 over 15 on transfer to cellular assay. Most 
cell lines required a concentration of greater than 100 μM for the 
death of 50% of cell population (LC50), with only 2 cell lines, 
SK-MEL-5 and UACC-62, showing any appreciable cytotoxicity.  
3. Conclusions  
In summary, we have explored the molecular space around the 
bisindolylmaleimide pharmacophore, generating 28 novel 
compounds and the development of novel anticancer leads. Our 
initial test compounds identified a dichotomy of activity with the 
maleimide headgroup 15 offering potent kinase inhibitory 
activity against all CDKs and GSK-3 while the 
hydroxymaleimide and removal of the indole methyl groups 22 
offers some selectivity of action albeit at lower potency.  
In order to assess the effect of substitution on potency and 
selectivity, a series of novel bisindolylhydroxymaleimides 
functionalized at the indole nitrogens were consequently 
synthesised and assessed for kinase inhibitory and anticancer 
activity. The move from azaindole to indole does not 
significantly affect potency or the GSK-3 kinase activity but does 
remove all CDK2 and CDK5 inhibition (but not CDK9). 
Converging towards a ruboxistaurin macrocyclic system is 
disappointingly associated with a complete loss of kinase activity 
and indeed anticancer activity as seen in the NCI screen but the 
majority of other substitutions are well tolerated. In addition to 
the significant potency of 15, bishexanitrile substituted 56 is a 
key lead compound for future development with evident GSK-3 
inhibition in the absence of other kinase activity in the screen. 
The anticancer activity of 15 in the NCI 60 cell line screen has 
uncovered sub-micromolar growth inhibition of cancer cells 
across the full panel and significant inhibition of SNB-75 CNS 
cancer, A498 and UO-31 renal and MDA-MB-435 melanoma 
cell lines. The fact that 56 progressed to five dose assay suggests 
that GSK-3 kinase has a likely role in its effect on cancer cell 
growth.  
Overall, our findings confirm that the insertion of an oxygen into 
the bisindolylmaleimide pharmacophore at the key headgroup is 
well tolerated and capable of low nanomolar kinase inhibition in 
particular with GSK-3 kinase. It is evident that this new binding 
platform is capable of imbuing discrete inhibitory activity on 
related target kinases and will be the focus of our future research.  
 
4. Experimental Section  
4.1 General procedures 
Solvents were distilled prior to use as follows: 
dichloromethane was distilled from phosphorous pentoxide; ethyl 
acetate was distilled from potassium carbonate; ethanol and 
methanol were distilled from magnesium in the presence of 
iodine; toluene was distilled from sodium and benzophenone; 
hexane was distilled prior to use; tetrahydrofuran was freshly 
distilled from sodium and benzophenone. Diethyl ether was 
obtained pure from Riedel-de Haën. Organic phases were dried 
using anhydrous magnesium sulfate. All commercial reagents 
were used without further purification unless otherwise stated. 
Infrared spectra were recorded as a thin film on sodium chloride 
plates for liquids or potassium bromide (KBr) disc for solids on a 
Perkin Elmer Spectrum 100 FT-IR spectrometer. 1H (300 MHz) 
and 13C (75 MHz) NMR spectra were recorded on a Bruker 
Avance 300 NMR spectrometer. 1H (400 MHz) NMR spectra 
were recorded on a Bruker Avance 400 NMR spectrometer. 1H 
(600 MHz) and 13C (150 MHz) NMR spectra were recorded on a 
Bruker Avance III 600 MHz NMR spectrometer equipped with a 
dual CH cryoprobe. All spectra were recorded at room 
temperature (~20 ºC) in deuterated chloroform (CDCl3) with 
tetramethylsilane (TMS) as an internal standard, or deuterated 
dimethylsulfoxide (DMSO-d6). 1H NMR spectra recorded in 
deuterated dimethylsulfoxide (DMSO-d6) were assigned using 
the DMSO-d6 peak as the reference peak. Chemical shifts (δH and 
δC) are expressed in parts per million (ppm) relative to the 
reference peak. Coupling constants (J) are expressed in Hertz 
(Hz). Splitting patterns in 1H NMR spectra are designated as s 
(singlet), br s (broad singlet), d (doublet), br d (broad doublet), t 
(triplet), q (quartet), dd (doublet of doublets), dt (doublet of 
triplets), ddd (doublet of doublet of doublets), ddt (doublet of 
doublet of triplets) and m (multiplet).  Low resolution mass 
spectra were recorded on a Waters Quattro Micro triple 
quadrupole spectrometer (QAA1202) in electrospray ionisation 
(ESI) mode using 50% acetonitrile – water containing 0.1% 
formic acid as eluent. High resolution mass spectra (HRMS) 
were recorded on a Waters LCT Premier Time of Flight 
spectrometer (KD160) in electrospray ionisation (ESI) mode 
using 50% acetonitrile – water containing 0.1% formic acid as 
eluent. All synthetic compounds were confirmed to be >95% 
pure by LCMS analysis using a 14 minute gradient method 
(90:10 to 10:90 water:acetonitrile with 0.1% formic acid as 
additive) on a Waters Alliance 2695 HPLC and a Waters Xterra 
Phenyl 3.5µm (2.1 x 100mm) HPLC column. Melting points 
were measured in a uni-melt Thomas Hoover capillary melting 
point apparatus and are uncorrected. Thin layer chromatography 
(TLC) was carried out on precoated silica gel plates (Merck 60 
PF254), and visualisation was achieved by UV light detection 
(254 nm). 
 
4.2  Kinase inhibition assays 
Kinase activities were assayed in appropriate kinase buffer, with 
either protein or peptide as substrate in the presence of 15µM [γ-
33P] ATP (3,000 Ci/mmol; 10 mCi/ml) in a final volume of 30 µl 
following the assay described.28,50 Controls were performed with 
appropriate dilutions of dimethylsulfoxide. Full-length kinases 
are used unless specified. Peptide substrates were obtained from 
ProteoGenix (Schiltigheim, France).  
The buffers used for kinase assays are the following: (A) 10 mM 
MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl pH 7.5, 50 
µg/mL heparin; (B) 60 mM β-glycerophosphate, 30 mM p-
nitrophenyl-phosphate, 25 mM MOPS (pH 7), 5 mM EGTA, 15 
mM MgCl2, 1 mM DTT, 0.1 mM sodium orthovanadate; (D) 25 
mM MOPS, pH7.2, 12.5 mM β-glycerolphosphate, 25 mM 
MgCl2, 5 mM EGTA, 2 mM EDTA, 0.25 mM DTT; (H) MOPS 
25 mM pH 7.5, 10 mM MgCl2; (R) 1.67 mM MOPS pH 7.2, 0.83 
mM β-glycerophosphate, 1.33 mM MgCl2, 0.83 mM MnCl2, 0.33 
mM EGTA, 0.13 mM EDTA, 16.67 µg/ml BSA, 0.017 mM 
DTT. 
A panel of ten native or recombinant protein kinases was used 
during this study: (i) HsRIPK3 (human, recombinant, expressed 
by baculovirus in Sf9 insect cells) was assayed in buffer R with 
0.1 µg/µl of MBP as substrate; (ii) HsPIM1 (human proto-
oncogene, recombinant, expressed in bacteria) was assayed in 
buffer B with 0.8 µg/µl of histone H1 (Sigma #H5505) as 
substrate; (iii) HsHaspin-kd (human, kinase domain, amino acids 
470 to 798, recombinant, expressed in bacteria) was assayed in 
buffer H with 0.007 µg/µl of Histone H3 (1-21) peptide 
(ARTKQTARKSTGGKAPRKQLA) as substrate; (iv) 
HsCDK2/CyclinA (human, cyclin-dependent kinase-2, kindly 
provided by Dr. A. Echalier-Glazer, Leicester, UK) was assayed 
in buffer A (supplemented with 0.15 mg/ml BSA and 0.23 mg/ml 
DTT) with 0.8 µg/µl of histone H1 as substrate; (v) 
HsCDK9/CyclinT (human, recombinant, expressed by 
baculovirus in Sf9 insect cells) was assayed in buffer A 
(supplemented with 0.15 mg/ml BSA and 0.23 mg/ml DTT) with 
0.27 µg/µl of the following peptide: 
YSPTSPSYSPTSPSYSPTSPSKKKK, as substrate; (vi) 
HsCDK5/p25 (human, recombinant, expressed in bacteria) was 
assayed in buffer B, with 0.8 µg/µl of histone H1 as substrate; 
(vii) HsAuroraB (human, recombinant, expressed by baculovirus 
in Sf9 insect cells, SignalChem, product #A31-10G) was assayed 
in buffer D with 0.2 µg/µl of MBP as substrate; (viii) SscGSK-
3α/β (Sus scrofa domesticus, glycogen synthase kinase-3, affinity 
purified from porcine brain) was assayed in buffer A 
(supplemented with 0.15 mg/ml BSA and 0.23 mg/ml DTT), with 
0.010 µg/µl of GS-1 peptide, a GSK-3-selective substrate 
(YRRAAVPPSPSLSRHSSPHQSpEDEEE, “Sp” stands for 
phosphorylated serine); (ix) SscCK1δ/ε (Sus scrofa domesticus, 
casein kinase 1δ/ε, affinity purified from porcine brain) was 
assayed in buffer B, with 0.022 µg/µl of the following peptide: 
RRKHAAIGSpAYSITA as CK1-specific substrate; (x) 
RnDYRK1A-kd (Rattus norvegicus, amino acids 1 to 499 
including the kinase domain, recombinant, expressed in bacteria, 
DNA vector kindly provided by Dr. W. Becker, Aachen, 
Germany) was assayed in buffer A (supplemented with 0.5 
mg/mL BSA and 0.23 mg/ml DTT) with 0.033 μg/µl of the 
following peptide: KKISGRLSPIMTEQ as substrate. 
 
4.3 NCI-60 anticancer screening56 
The experimental methodology involves initial growth of the 
tumour cell lines in RPMI 1640 medium containing 5% foetal 
bovine serum and 2 mM L-glutamine. For a typical screening 
experiment, cells are inoculated into 96 well microtiter plates in 
100 µL of medium at plating densities ranging from 5,000 to 
40,000 cells/well, depending on the doubling time of individual 
cell lines. After cell inoculation, the microtiter plates are 
incubated at 37 °C, 5% CO2, 95% air and 100% relative humidity 
for 24 hours prior to addition of candidate compounds. 
After 24 hours, two plates of each cell line are fixed in situ 
with trichloroacetic acid (TCA), to represent a measurement of 
the cell population for each cell line at the time of drug addition 
(Tz). Candidate compounds are dissolved in DMSO at 400-fold 
the desired final maximum test concentration and stored frozen 
prior to use. The single dose screen is carried out at a 
concentration of 10 µM. 
Following drug addition, the plates are incubated for an 
additional 48 hours at 37 °C, 5% CO2, 95% air, and 100% 
relative humidity. For adherent cells, the assay is terminated by 
the addition of cold TCA. Cells are fixed in situ by the gentle 
addition of 50 µL of cold 50% (w/v) TCA and incubated for 60 
minutes at 4 °C. Sulforhodamine B (SRB) solution (100 µL) at 
0.4% (w/v) in 1% acetic acid is added to each well, and plates are 
incubated for 10 minutes at room temperature. Absorbance is 
read on an automated plate reader at a wavelength of 515 nm, and 
using the absorbance measurements of time zero (Tz), control 
growth (C), and test growth in the presence of the drug at a 
concentration of 10 µM, the percentage growth is calculated.52 
 
4.4 Chemical Data 
For the synthesis of compounds (13), (15-19), (23-24), (26-27), 
(31-35), (37), (39) and (41) see the Supplementary Information. 
3-(1-Methyl-1H-indol-3-yl)-4-(1-methyl-1H-pyrrolo[2,3-
b]pyridin-3-yl)furan-2,5-dione (14) 
A solution of 1-methyl-1H-pyrrolo[2,3-b]pyridine 10 (1.808 g, 
13.7 mmol) in diethyl ether (80 mL) was cooled to 0 oC in an ice 
bath. Oxalyl chloride (1.39 mL, 16.4 mmol) was then added in a 
dropwise manner over a period of 20 minutes.57 The resulting 
mixture was stirred for 3 hours, whilst being allowed to slowly 
return to room temperature in that time. The solvent and excess 
oxalyl chloride was removed under reduced pressure and the 
solid residue was dissolved in DCM (60 mL). This was then 
added to a stirred solution containing 2-(1-methyl-1H-indol-3-
yl)acetic acid 13 (2.592 g, 13.7 mmol) and triethylamine (3.82 
mL, 27.4 mmol) in DCM (30 mL). The reaction mixture was 
stirred at room temperature for 14 hours, after which time the 
solvent was removed under reduced pressure. The dark red 
residue was subjected to flash column chromatography 
(hexane/ethyl acetate, 70:30), yielding maleic anhydride 14 as a 
red solid (1.796 g, 37%): m.p. 222-224 oC; vmax/cm-1 (KBr) 2919, 
1819, 1747, 1523, 1371, 1254; δH (300 MHz, CDCl3) 3.91 [3H, s, 
NCH3], 3.94 [3H, s, NCH3], 6.75 [1H, q, J 8.0, 4.7, C-H5’], 6.77-
6.79 [2H, m, C-H5,6], 7.13-7.19 [1H, m, C-H7], 7.30 [1H, dd, J 
8.0, 1.5, C-H4’], 7.34 [1H, d, J 8.3, C-H4], 7.85 [1H, s, C-H2], 
7.86 [1H, s, C-H2’], 8.25 [1H, dd, J 4.7, 1.5, C-H6’]; δC (75 MHz, 
CDCl3) 31.9 (CH3, NCH3), 33.6 (CH3, NCH3), 103.6 (C, aromatic 
C), 104.8 (C, aromatic C), 109.9 (CH, aromatic CH), 116.5 (CH, 
aromatic CH), 118.6 (C, aromatic C), 120.9 (CH, aromatic CH), 
122.3 (CH, aromatic CH), 123.0 (CH, aromatic CH), 125.5 (C, 
aromatic C), 126.4 (C, aromatic C), 128.1 (C, aromatic C), 130.5 
(CH, aromatic CH), 133.6 (CH, aromatic CH), 134.0 (CH, 
aromatic CH), 137.0 (C, aromatic C), 144.0 (CH, aromatic CH), 
147.8 (C, aromatic C), 166.6 (C, C=O), 166.8 (C, C=O); m/z 
(ES+) 358.1 [M+H]+ (100%); HRMS (ES+): Exact mass 
calculated for (C21H16N3O3)+ 358.1192. Found 358.1185. 
3-(1-Acetyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(1-
(phenylsulfonyl)-1H-indol-3-yl)furan-2,5-dione 20 
A suspension of potassium 2-oxo-2-(1H-pyrrolo[2,3-b]pyridin-3-
yl)acetate 18 (4.05 g, 17.7 mmol) and 2-(1-(phenylsulfonyl)-1H-
indol-3-yl)acetic acid 19 (5.56 g, 17.63 mmol) were stirred in 
acetic anhydride (40 mL) at 80oC for 24 hours. Following this, 
the mixture was vacuum filtered. The collected solid was stirred 
in boiling ethyl acetate (100 mL) for 20 minutes before being 
filtered hot to remove insoluble impurities and the protected 
maleic anhydride recrystallized from ethyl acetate/hexane as a 
bright yellow solid (3.292 g). Further work-up of the mother 
liquor yielded a yellow/brown solid which was purified by flash 
column chromatography (80:20, hexane/ethyl acetate) to yield a 
further batch of the protected maleic anhydride (0.532 g, 
combined yield 3.824 g, 42%): m.p. 123 – 125oC; νmax/cm-1 
(KBr) 3432, 3139, 2929, 1831, 1764, 1724, 1645, 1547, 1375; δH 
(300 MHz, DMSO-d6) 3.01 (s, 3H, OAc), 6.50 (q, 1H, J =  8.0, 
4.7 Hz, C-H5), 6.89 (dd, 1H, J = 8.0, 1.7 Hz, C-H6’), 6.99 (m, 2H, 
C-H3’’, H5’’), 7.28 (ddd, 1H, J = 8.5, 1.8 Hz, C-H7’), 7.67 (t, 2H, J 
= 8.0 Hz, C-H4’, H5’), 7.80 (d, 1H, J = 7.5 Hz, C-H4’’), 7.96 (d, 
1H, J = 8.5 Hz, C-H4), 8.06 (m, 2H, C-H2’’, H6’’), 8.23 (s, 1H, C-
H2’), 8.25 (dd, 1H, J = 4.7, 1.5 Hz, C-H6), 8.47 (s, 1H, C-H2); m/z 
(ES-) 468.2 (M-AcO-) 90%;  HRMS (ES+): Exact mass 
calculated for (C25H15N3O5S)+ 468.0654. Found 468.0661. 
3-(1H-Indol-3-yl)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)furan-2,5-
dione 21 
A suspension of 3-(1-acetyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-(1-
(phenylsulfonyl)-1H-indol-3-yl)furan-2,5-dione 20 (1.64 g, 3.21 
mmol) and potassium hydroxide (1.07 g, 19.2 mmol) in aqueous 
methanol (4:1 MeOH:Water, 50 mL) was heated to reflux for 24 
hours. Following this, the mixture was concentrated under 
reduced pressure, water (20 mL) was added to the residue, the pH 
was adjusted to 5 using 2 M HCl and the mixture was extracted 
with ethyl acetate (3 x 30 mL). The combined organic extracts 
were washed with saturated aqueous sodium bicarbonate solution 
(1 x 15 mL), water (2 x 20 mL), brine (1 x 30 mL), dried and 
concentrated under reduced pressure to yield a glassy red solid. 
Purification by flash column chromatography (70:30 – 60:40, 
hexane/ethyl acetate gradient elution) to yield the deprotected 
maleic anhydride as an orange solid (0.283 g, 27%): m.p. 299 – 
301oC; νmax/cm-1 (KBr) 3435, 3020, 2882, 1839, 1820, 1751, 
1631, 1532; δH (400 MHz, DMSO-d6) 6.71-6.75 (m, 2H, C-H5’, 
C-H4), 6.79 (q, 1H, J = 8.0, 4.7 Hz, C-H5), 7.05 (ddd, 1H, J = 8.2, 
1.3 Hz, C-H6’), 7.24 (dd, 1H, J = 8.1, 1.7 Hz, C-H7’), 7.45 (d, 1H, 
J = 8.0 Hz, C-H4’), 7.91 (s, 1H, C-H2’), 7.95 (s, 1H, C-H2), 8.17 
(dd, 1H, J = 4.6, 1.5 Hz, C-H6), 12.02 (brs, 1H, indole N-H), 
12.39 (brs, 1H, 7-azaindole N-H); δC (100 MHz, DMSO-d6) 
103.7 (C, aromatic C), 104.6 (C, aromatic C), 112.2 (CH, 
aromatic CH), 116.1 (CH, aromatic CH), 117.5 (C, aromatic C), 
120.0 (CH, aromatic CH), 121.0 (CH, aromatic CH), 122.2 (CH, 
aromatic CH), 124.6 (C, aromatic C), 127.1 (C, aromatic C), 
129.1 (C, aromatic C), 129. 3 (CH, aromatic CH), 130.5 (CH, 
aromatic CH), 130.8 (CH, aromatic CH), 136.2 (C, aromatic C), 
143.6 (CH, aromatic CH), 148.4 (C, aromatic C), 166.2 (C, 
C=O), 166.4 (C, C=O); m/z (ES+) 330.2 (M+H+) 100%; HRMS 




To a mixture of 3-(1H-indol-3-yl)-4-(1H-pyrrolo[2,3-b]pyridin-
3-yl)furan-2,5-dione 21 (0.132 g, 0.4 mmol) and 
hydroxylammonium hydrochloride (0.109 g, 1.57 mmol) in DMF 
(1 mL) was added triethylamine (0.21 mL, 1.51 mmol). The 
mixture was allowed to stir for 24 hours at 80oC. Following this, 
1 M HCl (10 mL) was added. The mixture was extracted with 
ethyl acetate (3 x 5 mL). The combined organic extracts were 
washed with water (2 x 10 mL), brine (1 x 10 mL), dried and 
concentrated under reduced pressure to yield the 
hydroxymaleimide as a deep red solid (0.112 g, 83%):  m.p. 
>300oC; νmax/cm-1 (KBr) 3340, 1777, 1721, 1703, 1645, 1539, 
1419, 1133, 1100, 1026, 726; δH (400 MHz, DMSO-d6) 6.65 (t, 
1H, J = 7 Hz, C-H5’), 6.70 (s, 1H, C-H7’), 6.72 (q, 1H, J = 8.1, 
4.6 Hz, C-H5), 7.00 (t, 1H, J = 7.6 Hz, C-H6’), 7.15 (dd, 1H, J = 
8.0, 1.2 Hz, C-H4), 7.41 (d, 1H, J = 8.0 Hz, C-H4’), 7.86 (s, 1H, 
C-H2’), 7.87 (s, 1H, C-H2), 8.11 (dd, 1H, J = 4.5, 1.2 Hz, C-H6), 
10.48 (brs, 1H, indole N-H), 11.81 (brs, 1H, 7-azaindole N-H), 
12.24 (brs, 1H, N-OH); δC (100 MHz, DMSO-d6) 104.3 (C, 
aromatic C), 105.1 (C, aromatic C), 112.0 (CH, aromatic CH), 
115.1 (CH, aromatic CH), 117.7 (C, aromatic C), 119.6 (CH, 
aromatic CH), 120.7 (CH, aromatic CH), 121.9 (CH, aromatic 
CH), 123.4 (C, aromatic C), 125.0 (C, aromatic C), 125.2 (C, 
aromatic C), 129.0 (CH, aromatic CH), 129.5 (CH, aromatic 
CH), 129.7 (CH, aromatic CH), 136.0 (C, aromatic C), 143.2 
(CH, aromatic CH), 148.3 (C, aromatic C), 168.2 (C, C=O), 
168.3 (C, C=O); m/z (ES-) 343.3 (M-H-) 100%; HRMS (ES+): 




 A mixture of potassium 2-(1H-indol-3-yl)-2-oxoacetate 24 
(3.677 g, 15.8 mmol), 2-[1-(phenylsulfonyl)-1H-indol-3-yl]acetic 
acid 19 (5.020 g, 15.8 mmol) and acetic anhydride (30 mL) was 
stirred at 80 °C for 24 hours. The yellow suspension was then 
cooled to room temperature and filtered. The solid collected was 
stirred in boiling ethyl acetate for 30 minutes before hot filtration 
removed a white side product. The yellow filtrate was 
concentrated to dryness giving a yellow crystalline solid (2.426 
g). The acetic anhydride solution from the initial filtration was 
concentrated under reduced pressure. The residue was then 
washed with saturated sodium bicarbonate solution (50 mL) and 
extracted into ethyl acetate (3 × 30 mL). The organic layer was 
filtered before being washed with saturated sodium bicarbonate 
solution (30 mL), followed by water (30 mL) and brine (30 mL) 
and then dried over anhydrous magnesium sulfate, filtered and 
the solvent evaporated under reduced pressure. The crude residue 
was recrystallised from ethyl acetate to give additional product 
(0.544 g, combined yield 2.970 g, 40%): m.p. 223-225 °C; 
νmax/cm-1 (KBr) 3139, 1830, 1762, 1718, 1373, 1176; δH (300 
MHz, DMSO-d6) 2.69 (3H, s, CH3), 6.44 [1H, t, J 7.4, C(6′)-H], 
6.59 [1H, d, J 7.8, C(7′)-H], 6.95 [1H, t, J 7.3, C(6)-H], 7.03 [1H, 
d, J 7.6, C(7)-H], 7.16 [1H, t, J 7.8, C(5′)-H], 7.27 [1H, t, J 7.7, 
C(5)-H], 7.61-7.71 [2H, m, C(3′′, 5′′)-H], 7.75-7.85 [1H, t, J 7.4, 
C(4′′)-H], 7.93 [1H, d, J 8.6, C(4)-H], 7.98-8.06 [2H, m, C(2′′, 
6′′)-H], 8.19 [1H, s, C(2′)-H], 8.26 [1H, d, J 8.3, C(4′)-H], 8.30 
[1H, s, C(2)-H]; δC (75 MHz, DMSO-d6) 23.9 (CH3), 109.3 (C, 
aromatic C), 111.2 (C, aromatic C), 113.1 (CH, aromatic CH), 
115.9 (CH, aromatic CH), 120.5 (CH, aromatic CH), 121.6 (CH, 
aromatic CH), 123.1 (CH, aromatic CH), 123.7 (CH, aromatic 
CH), 125.4 (CH, aromatic CH), 125.7 (CH, aromatic CH), 126.6 
(C, aromatic C), 126.9 (2CH, 2 × aromatic CH), 127.6 (C, 
aromatic C), 129.6 (CH, aromatic CH), 130.1 (2CH, 2 × aromatic 
CH, C, aromatic C), 130.8 (CH, aromatic CH), 131.4 (C, 
aromatic C), 133.6 (C, aromatic C), 134.7 (C, aromatic C), 135.2 
(CH, aromatic CH), 136.4 (C, aromatic C), 164.9 (C=O), 165.1 
(C=O), 169.7 (C=O); m/z (ESI+) 511.1 [(M+H)+ 10%]; HRMS 




To a solution of 3,4-di(1H-indol-3-yl)furan-2,5-dione  26 
(5.004 g, 15.2 mmol) in anhydrous DMF (80 mL) at 0°C 
under a nitrogen atmosphere was added sodium hydride (60 
wt. % oil dispersion, 0.640 g, 16.0 mmol). The dark purple 
solution was stirred for 30 minutes while warming to room 
temperature before 6-bromohexanenitrile (2.62 mL, 3.47 g, 
19.7 mmol) was added. The solution was stirred for 16 hours 
before being poured into water (200 mL) and extracted with 
ethyl acetate (3 × 60 mL). The combined organic layers were 
washed with 1 M aqueous HCl (2 × 60 mL) followed by water 
(60 mL) before being dried over anhydrous magnesium 
sulfate, filtered and the solvent evaporated under reduced 
pressure. The crude material was purified using column 
chromatography on silica gel with 20:80 – 30:70 ethyl 
acetate/hexane to give 2 fractions found to be the mono 




3,1-diyl))dihexanenitrile 28 was isolated as a red solid (1.658 
g, 21%): m.p. 120-122 °C; νmax/cm-1
  (KBr) 3435, 2939, 2243, 
1815, 1749, 1525, 1257, 747; δH  (300 MHz, DMSO-d6) 
1.27-1.40 [4H, m, 2 × C(4′′)-H2], 1.57 [4H, quin, J 7.4, 2 × 
C(3′′)-H2], 1.76 [4H, quin, J 7.3, 2 × C(5′′)-H2], 2.45 [4H, t, J 
7.0, 2 ×C(2′′)-H2], 4.27 [4H, t, 2 × C(6′′)-H2], 6.75 [2H, t, J 
7.4, C(6, 6′)-H], 6.87 [2H, d, J 7.9, C(7, 7′)-H], 7.10 [2H, t, J 
7.7, C(5, 5′)-H], 7.55 [2H, d, J 8.3, C(4, 4′)-H], 7.90 [2H, s, 
C(2, 2′)-H]; δc (75 MHz, DMSO-d6)  16.0 (2 × CH2), 24.3 
(2 × CH2), 25.1 (2 × CH2), 28.7 (2 × CH2), 45.6 (2 × CH2), 
104.2 (2C, 2 × aromatic C), 110.6 (2CH, 2 × aromatic CH), 
120.0 (2CH, 2 × aromatic CH), 120.5 (2 × CN), 121.5 (2CH, 
2 × aromatic CH), 122.2 (2CH, 2 × aromatic CH), 125.3 (2C, 2 
× aromatic C), 127.6 (2C, 2 × aromatic C), 133.1 (2CH, 2 × 
aromatic CH), 136.0 (2C, 2 × aromatic C), 166.3 (2 × 
C=O); m/z (ESI+) 519.2 [(M+H)+  10%]; HRMS (ESI+): 
Exact mass calculated for (C32H31N4O3)
+ 519.2396. Found 
519.2401. 
6-{3-[4-(1H-Indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl]-1H-
indol-1-yl}hexanenitrile 29 was isolated as a red solid (0.953 g, 
15%): m.p. 102-104 °C; νmax/cm-1 (KBr) 3391, 2935, 2246, 
1819, 1748, 1529, 1251, 743; δH  (300 MHz, DMSO-d6) 
1.32 [2H, m, C(4′′)-H2], 1.57 [2H, quin, J 7.3, C(3′′)-H2], 
1.74 [2H, quin, J 7.3, C(5′′)-H2], 2.45 [2H, t, J 7.1, C(2′′)-H2], 
4.26 [2H, t, J 7.0, C(6′′)-H2], 6.69 [1H, ddd, J 7.9, 6.9, 0.9, 
C(6)-H], 6.74-6.82 [2H, m, C(6′, 7)-H], 6.95 [1H, d, J 7.8, 
C(7′)-H], 7.04 [1H, ddd, J 8.2, 7.1, 1.2, C(5)-H], 7.10 [1H, 
ddd, J 8.2, 7.2, 1.1, C(5′)-H], 7.43 [1H, d, J 8.2, C(4)-H], 7.55 
[1H, d, J 8.2, C(4′)-H], 7.86 [1H, s, C(2′)-H], 7.89 [1H, s, C(2)-
H], 11.92 (1H, bs, NH); δc  (75 MHz, DMSO-d6) 16.0 (CH2), 
24.3 (CH2), 25.2 (CH2), 28.7 (CH2), 45.6 (CH2), 104.2 (C, 
aromatic C), 104.9 (C, aromatic C), 110.5 (CH, aromatic 
CH), 112.1 (CH, aromatic CH), 119.8 (CH, aromatic CH), 
120.0 (CH, aromatic CH), 120.5 (CN), 121.2 (CH, aromatic 
CH), 121.4 (CH, aromatic CH), 122.1 (CH, aromatic CH), 
122.2 (CH, aromatic CH), 124.7 (C, aromatic C), 125.5 (C, 
aromatic C), 127.4 (C, aromatic C), 128.2 (C, aromatic C), 
130.6 (CH, aromatic CH), 133.0 (CH, aromatic CH), 135.9 
(C, aromatic C), 136.2 (C, aromatic C), 166.36 (C=O), 
166.43 (C=O); m/z (ESI+) 424.2 [(M+H)+  100%]; HRMS 
(ESI+): Exact mass calculated for (C26H22N3O3)
+  
424.1661. Found 424.1659. 
6-{3-[4-(1H-Indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl]-
1H-indol-1-yl}hexanoic acid 30 
6-{3-[4-(1H-Indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl]-1-
indol-1-yl}hexanenitrile 29 (0.402 g, 0.950 mmol) was 
dissolved in a mixture of methanol (20 mL) and 10% aqueous 
potassium hydroxide solution (20 mL). The solution was heated 
to reflux for 16 hours before being allowed to cool and the 
solvent evaporated under reduced pressure. The residue was 
dissolved in water (20 mL) and acidified to pH 2 using 20% 
aqueous HCl, and then extracted with ethyl acetate (20 mL × 2). 
The organic layer was washed with water (20 mL × 2) followed 
by brine (20 mL) before being dried over anhydrous magnesium 
sulfate, filtered and the solvent evaporated under reduced 
pressure to give desired compound as a red solid (0.335 g, 
84%): 198-199 °C; νmax/cm-1  (KBr) 3386, 2924, 1816, 1740, 
1699, 1531, 1261; δH (300 MHz, DMSO-d6) 1.23 [2H, quin, J 
7.5, C(4′′)- H2], 1.51 [2H, quin, J 7.5, C(3′′)-H2], 1.72 [2H, 
quin, J 7.2, C(5′′)-H2], 2.17 [2H, t, J 7.3, C(2′′)-H2], 4.24 [2H, 
t, J 7.0, C(6′′)-H2], 6.67 [1H, t, J 7.5, C(6)-H], 6.76 [1H, t, J 
7.8, C(6′)-H], 6.77 [1H, d, J 7.5, C(7)-H], 6.93 [1H, d, J 8.0, 
C(7′)-H], 7.04 [1H, t, J 8.0, C(5)-H], 7.09 [1H, t, J 7.8, C(5′)-
H], 7.43 [1H, d, J 8.1, C(4)-H], 7.53 [1H, d, J 8.3, C(4′)-H], 
7.84 [1H, s, C(2′)-H], 7.89 [1H, s, C(2)-H], 11.92 (1H, bs, NH), 
11.99 (1H, bs, COOH); δc (75 MHz, DMSO-d6) 24.0 (CH2), 
25.6 (CH2), 29.3 (CH2), 33.5 (CH2), 45.7 (CH2), 104.2 (C, 
aromatic C), 104.9 (C, aromatic C), 110.5 (CH, aromatic CH), 
112.1 (CH, aromatic CH), 119.8 (CH, aromatic CH), 120.0 
(CH, aromatic CH), 121.2 (CH, aromatic CH), 121.4 (CH, 
aromatic CH), 122.07 (CH, aromatic CH), 122.12 (CH, 
aromatic CH), 124.7 (C, aromatic C), 125.5 (C, aromatic C), 
127.4 (C, aromatic C), 128.2 (C, aromatic C), 130.6 (CH, 
aromatic CH), 133.0 (CH, aromatic CH), 135.9 (C, aromatic C), 
136.1 (C, aromatic C), 166.4 (C=O), 166.5 (C=O), 174.3 
(COOH); m/z (ESI-) 441.2 [(M-H)-  100%]; HRMS (ESI+): 
Exact mass calculated for (C26H23N2O5)+ 443.1607. Found 
443.1611. 
 
Synthesis of N-isopropyl maleic anhydride intermediate 
Potassium 2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetate 36 
A solution of 2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetic acid 34 
(3.499 g, 15.1 mmol) in ethanol (50 mL) was treated with 
potassium hydroxide (85 wt. %, 0.993 g, 15.1 mmol) and the 
mixture was stirred at room temperature for 4 hours. The 
solvent was removed under reduced pressure and the residue 
dried overnight at 40 °C to give the desired product as a pale 
pink solid (3.961 g, 97%): m.p. 80-84 °C; νmax/cm-1 (KBr) 3456, 
2981, 1649, 1607, 1301, 1203, 738; δH (300 MHz, DMSO-d6) 
1.48 [d, 6H, J 6.6, CH(CH3)2], 4.80 [1H, sept, J 6.7, CH(CH3)2], 
7.17 [1H, ddd, J 8.2, 7.2, 1.1, C(5)-H], 7.22 [1H, ddd, J 8.5, 7.1, 
1.4, C(6)-H], 7.58 [1H, d, J 7.6, C(7)-H], 8.14 [1H, s, C(2)-H], 
8.19 [1H, d, J 7.3, C(4)-H]; δc (75 MHz, DMSO-d6) 22.2 (2 × 
CH3), 47.2 [CH(CH3)2], 110.5 (CH, aromatic CH), 113.4 (C, 
aromatic C), 121.4 (CH, aromatic CH), 121.5 (CH, aromatic 
CH), 122.2 (CH, aromatic CH), 126.5 (C, aromatic C), 134.0 
(CH, aromatic CH), 135.8 (C, aromatic C), 169.8 (C=O), 193.1 
(C=O); m/z (ESI+) 232.3 [(M+2H)+, 100%]; HRMS (ESI+): 
Exact mass calculated for (C13H17N2O3)+ 249.1239 
[(M+NH4+H)+]. Found 249.1239. 
3-(1-Isopropyl-1H-indol-3-yl)-4-[1-(phenylsulfonyl)-1H-
indol-3-yl]furan-2,5-dione 38 
A mixture of potassium 2-(1-isopropyl-1H-indol-3-yl)-2-
oxoacetate 36 (3.502 g, 13.0 mmol), 2-[1-(phenylsulfonyl)-1H-
indol-3-yl]acetic acid 19 (4.096 g, 13.0 mmol) and acetic 
anhydride (30 mL) was stirred at 80 °C for 24 hours. The 
yellow suspension was then allowed to cool to room 
temperature and the solvent was evaporated under reduced 
pressure. The residue was washed with saturated aqueous 
sodium bicarbonate (50 mL) and extracted into ethyl acetate (2 
× 30 mL). The organic layer was washed with saturated 
aqueous sodium bicarbonate (30 mL), followed by water (30 
mL) and brine (30 mL) before being dried over anhydrous 
magnesium sulfate, filtered and the solvent evaporated under 
reduced pressure. The crude product was then purified using 
column chromatography on silica gel with 10% ethyl 
acetate/hexane to give a yellow foamy residue which was 
dissolved in chloroform (15 mL) and diethyl ether was added 
until a yellow solid precipitated which was collected by vacuum 
filtration (1.582 g, 24%): m.p. 102-105 °C; νmax/cm-1 (KBr) 
3561, 3135, 2977, 1821, 1755, 1631, 1536, 1372, 1185; δH (300 
MHz, DMSO-d6) 1.35 [6H, d, J 6.6, CH(CH3)2], 4.80 [1H, sept, 
J 6.6, CH(CH3)2], 6.39 [1H, t, J 7.6, C(6′)-H], 6.70 [1H, d, J 
8.0, C(7′)-H], 6.83-6.93 [2H, m, C(6, 7)-H], 7.05 [1H, t, J 7.7, 
C(5′)-H], 7.26 [1H, ddd, J 8.3, 6.9, 1.5, C(5)-H], 7.54 [1H, d, J 
8.4, C(4′)-H], 7.63-7.69 [2H, m, C(3′′, 5′′)-H], 7.80 [1H, m, 
C(4′′)-H], 7.91 [1H, s, C(2′)-H], 7.95 [1H, d, J 8.3, C(4)-H], 
8.04-8.07 [2H, m, C(6′′, 2′′)-H], 8.15 [1H, s, C(2)-H]; δc (75 
MHz, DMSO-d6) 22.0 (2 × CH3), 47.5 [CH(CH3)2], 104.1 (C, 
aromatic C), 110.9 (CH, aromatic CH), 112.0 (C, aromatic C), 
113.2 (CH, aromatic CH), 120.7 (CH, aromatic CH), 121.0 
(CH, aromatic CH), 121.7 (CH, aromatic CH), 122.5 (CH, 
aromatic CH), 122.8 (C, aromatic C), 123.4 (CH, aromatic CH), 
125.0 (C, aromatic C), 125.4 (CH, aromatic CH), 126.9 (2CH, 2 
× aromatic CH), 127.6 (C, aromatic C), 128.6 (CH, aromatic 
CH), 130.0 (2CH, 2 × aromatic CH), 130.9 (CH, aromatic CH), 
133.7 (C, aromatic C), 134.2 (C, aromatic C), 135.0 (CH, 
aromatic CH), 135.7 (C, aromatic C), 136.6 (C, aromatic C), 
165.5 (C=O), 165.8 (C=O); m/z (ESI+) 511.1 [(M+H)+ 50%]; 
HRMS (ESI+): Exact mass calculated for (C29H23N2O5S)+ 
511.1328. Found 511.1310. 
3-(1H-Indol-3-yl)-4-(1-isopropyl-1H-indol-3-yl)furan-2,5-
dione 40 
To a stirred suspension of 3-(1-isopropyl-1H-indol-3-yl)-4-[1-
(phenylsulfonyl)-1H-indol-3-yl]furan-2,5-dione 38 (1.353 g, 
2.37 mmol) in a mixture of methanol (60 mL) and water (15 
mL) was added potassium hydroxide (85 wt. %, 1.053 g, 15.9 
mmol). The mixture was then heated to reflux for 24 hours 
before being allowed to cool and the solvent evaporated under 
reduced pressure. The residue was acidified to pH 2 using 10% 
aqueous HCl and extracted with ethyl acetate (3 × 25 mL). the 
combined organic layers were washed with water (3 × 30 mL) 
and brine (30 mL) before being dried over anhydrous 
magnesium sulfate, filtered and the solvent evaporated under 
reduced pressure to give the desired product as red solid 
(0.764g, 87%): m.p. 186-188 °C; νmax/cm-1 (KBr) 3118, 2971, 
1812, 1745, 1627, 1529, 1247; δH (300 MHz, DMSO-d6) 1.38 
[6H, d, J 6.7, CH(CH3)2], 4.81 [1H, sept, J 6.6, CH(CH3)2], 
6.68-6.71 [2H, m, C(6, 7)-H], 6.85 [1H, ddd, J 8.1, 6.9, 0.7, 
C(6′)-H], 7.03-7.17 [3H, m, C(5, 5′, 7′)-H], 7.44 [1H, d, J 8.1, 
C(4)-H], 7.59 [1H, d, J 8.2, C(4′)-H], 7.75 [1H, s, C(2′)-H], 
7.92 [1H, d, J 2.9, C(2)-H], 11.94 (1H, bs, N-H); δc (75 MHz, 
DMSO-d6) 22.1 (2 × CH3), 47.2 (CH), 104.4 (C, aromatic C), 
104.8 (C, aromatic C), 110.6 (CH, aromatic CH), 112.2 (CH, 
aromatic CH), 119.9 (CH, aromatic CH), 120.2 (CH, aromatic 
CH), 121.4 (CH, aromatic CH), 121.6 (CH, aromatic CH), 
122.1 (2CH, 2 × aromatic CH), 124.2 (C, aromatic C), 125.6 (C, 
aromatic C), 127.2 (C, aromatic C), 128.5 (C, aromatic C), 
129.5 (CH, aromatic CH), 130.9 (CH, aromatic CH), 135.5 (C, 
aromatic C), 136.3 (C, aromatic C), 166.3 (C=O), 166.5 (C=O); 
m/z (ESI-) 369.3 [(M-H)- 100%]; HRMS (ESI+): Exact mass 
calculated for (C23H19N2O3)+ 371.1396. Found 371.1395. 
 
Substitutions on methyl intermediate 
3-(1-Ethyl-1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)furan-
2,5-dione 42  
To a solution of 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-
yl)furan-2,5-dione 39 (0.262 g, 0.76 mmol) in anhydrous DMF 
(15 mL) under nitrogen was added sodium hydride (60 wt. % oil 
dispersion, 0.037 g, 1.1 mmol) and the mixture was allowed to 
stir for 40 minutes at room temperature. Iodoethane (0.09 mL, 
0.17 g, 1.1 mmol) was then added and the reaction was stirred for 
a further 16 hours. Water (30 mL) was then added and the 
mixture was extracted with ethyl acetate (3 × 20 mL). The 
combined organic layers were then washed with 1 M aqueous 
HCl (2 × 20 mL), followed by water (20 mL) and brine (20 mL) 
before being dried over anhydrous magnesium sulfate, filtered 
and the solvent evaporated under reduced pressure. The crude 
residue was purified using column chromatography on silica gel 
with 20% ethyl acetate/hexane to give desired product as a red 
solid (0.204 g, 72%): m.p. = 214-216 °C; νmax/cm-1 (KBr) 3420, 
3133, 1816, 1758, 1626, 1525, 1219, 737; δH (300 MHz, DMSO-
d6) 1.31 (3H, t, J 7.2, CH2CH3), 3.89 (3H, s, CH3), 4.26 (2H, q, J 
7.2, CH2CH3), 6.67-6.74 [2H, m, C(6′, 7′)-H], 6.81 [1H, t, J 7.9, 
C(6)-H], 7.04 [1H, d, J 8.0, C(7)-H], 7.08-7.16 [2H, m, (5, 5′)-
H], 7.50 [1H, d, J 8.4, C(4′)-H], 7.54 [1H, d, J 8.4, C(4)-H], 7.81 
[1H, s, C(2)-H], 7.97 [1H, s, C(2′)-H]; δc (75 MHz, DMSO-d6) 
15.1 (CH2CH3), 33.0 (CH3), 40.8 (CH2CH3), 103.9 (C, aromatic 
C), 104.2 (C, aromatic C), 110.4 (CH, aromatic CH), 110.5 (CH, 
aromatic CH), 120.05 (CH, aromatic CH), 120.08 (CH, aromatic 
CH), 121.5 (CH, aromatic CH), 121.6 (CH, aromatic CH), 122.2 
(2CH, 2 × aromatic CH), 124.9 (C, aromatic C), 125.7 (C, 
aromatic C), 127.1 (C, aromatic C), 127.7 (C, aromatic C), 132.5 
(CH, aromatic CH), 134.4 (CH, aromatic CH), 135.6 (C, 
aromatic C), 136.8 (C, aromatic C), 166.3 (C=O), 166.5 (C=O); 
m/z (ESI+) 371.1 [(M+H)+ 100%]. HRMS (ESI+): Exact mass 
calculated for (C23H19N2O3)+ 371.1396. Found 371.1389. 
6-{3-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-
dihydrofuran-3-yl]-1H-indol-1-yl}hexanenitrile 43 
To a solution of 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3- 
yl)furan-2,5-dione 39 (0.505 g, 1.48 mmol) in anhydrous DMF 
(20 mL) under nitrogen was added sodium hydride (60 wt. % 
oil dispersion, 0.070 g, 1.77 mmol) and the mixture was stirred 
for 40 minutes at room temperature. 6-Bromohexane nitrile 
(0.30 mL, 0.38 g, 2.2 mmol) was then added and the reaction 
was stirred for a further 16 hours. Water (40 mL) was then 
added and the mixture was extracted with ethyl acetate (3 × 30 
mL). The combined organic layers were then washed with 1 M 
aqueous HCl (2 × 30 mL), followed by water (30 mL) and brine 
(30 mL) before being dried over anhydrous magnesium sulfate, 
filtered and the solvent evaporated under reduced pressure. The 
crude residue was purified using column chromatography on 
silica gel with 30% ethyl acetate/hexane to give desired product 
as a red solid (0.258 g, 40%): m.p. 78-79 °C; νmax/cm-1 (KBr) 
3411, 2936, 2244, 1816, 1750, 1529, 1254, 1100, 741; δH (400 
MHz, DMSO-d6) 1.27-1.35 [2H, m, C(4′′)-H2], 1.56 [2H, quin, 
J 7.4, C(3′′)-H2], 1.73 [2H, quin, J 7.4, C(5′′)-H2], 2.44 [2H, t, 
J 6.9, C(2′′)-H2], 3.89 (3H, s, CH3), 4.24 [2H, t, J 6.9, C(6′′)-
H2], 6.69-6.72 [2H, m, C(6′, 7′)-H], 6.79 [1H, t, J 7.6, C(6)-H], 
7.01 [1H, d, J 8.15, C(7)-H], 7.07-7.13 [2H, m, (5, 5′)-H], 7.49 
[1H, d, J 8.15, C(4′)-H], 7.54 [1H, d, 8.49, C(4)-H], 7.82 [1H, s, 
C(2)-H], 7.97 [1H, s, C(2′)-H]; δc (75 MHz, DMSO-d6)  16.0 
(CH2), 24.3 (CH2), 25.1 (CH2), 28.7 (CH2), 33.0 (CH3), 45.6 
(CH2), 103.9 (C, aromatic C), 104.3 (C, aromatic C), 110.50 
(CH, aromatic CH), 110.54 (CH, aromatic CH), 120.0 (CH, 
aromatic CH), 120.1 (CH, aromatic CH), 120.5 (CN), 121.4 
(CH, aromatic CH), 121.5 (CH, aromatic CH), 122.1 (CH, 
aromatic CH), 122.2 (CH, aromatic CH), 125.0 (C, aromatic C), 
125.7 (C, aromatic C), 127.0 (C, aromatic C), 127.9 (C, 
aromatic C), 132.9 (CH, aromatic CH), 134.3 (CH, aromatic 
CH), 135.9 (C, aromatic C), 136.7 (C, aromatic C), 166.3 
(C=O), 166.5 (C=O); m/z (ESI+) 438.2 [(M+H)+  12%]; 
HRMS (ESI+): Exact mass calculated for (C27H24N3O3)+  
438.1818. Found 438.1802. 
6-{3-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-
dihydrofuran-3-yl]-1H-indol-1-yl}hexanoic acid 44 
6-{3-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-
3-yl]-1H-indol-1-yl}hexanenitrile 43 (0.103 g, 0.235 mmol) 
was dissolved in a mixture of methanol (8 mL) and 10% 
aqueous potassium hydroxide solution (8 mL). The solution was 
heated to reflux for 16 hours before being allowed to cool and 
the solvent evaporated. The residue was dissolved in water (10 
mL) and acidified to pH 2 using 20% aqueous HCl, and was 
then extracted with ethyl acetate (10 mL × 2). The organic layer 
was washed with water (10 mL × 2) followed by brine (10 mL) 
before being dried over anhydrous magnesium sulfate, filtered 
and the solvent evaporated under reduced pressure to give 
desired compound as a red solid (0.082 g, 76%): m.p. 95-97 °C; 
νmax/cm-1 (KBr) 3050, 2937, 1816, 1751, 1705, 1611, 1528, 
1255, 740; δH (300 MHz, DMSO-d6) 1.18-1.29 [2H, m, C(4′′)-
H2], 1.51 [2H, quin, J 7.4, C(3′′)-H2], 1.71 [2H, quin, J 7.3, 
C(5′′)-H2], 2.17 [2H, t, J 7.4, C(2′′)-H2], 3.90 (3H, s, CH3), 
4.23 [2H, t, J 6.7, C(6′′)-H2], 6.68 [2H, m, C(6′, 7′)-H], 6.78 
[1H, t, J 7.6, C(6)-H], 7.00 [1H, d, J 8.0, C(7)-H], 7.06-7.14 
[2H, m, (5, 5′)-H], 7.48 [1H, d, J 8.3, C(4′)-H], 7.53 [1H, d, J 
8.3, C(4)-H], 7.81 [1H, s, C(2)-H], 7.99 [1H, s, C(2′)-H], 11.99 
(COOH); δc (75 MHz, DMSO-d6) 24.1 (CH2), 25.9 (CH2), 
29.3 (CH2), 33.0 (CH3), 33.8 (CH2), 45.7 (CH2), 103.9 (C, 
aromatic C), 104.2 (C, aromatic C), 110.48 (CH, aromatic CH), 
110.52 (CH, aromatic CH), 120.0 (2CH, 2 × aromatic CH), 
121.4 (2CH, 2 × aromatic CH), 122.1 (2CH, 2 × aromatic CH), 
125.0 (C, aromatic C), 125.7 (C, aromatic C), 127.0 (C, 
aromatic C), 127.8 (C, aromatic C), 132.9 (CH, aromatic CH), 
134.3 (CH, aromatic CH), 135.9 (C, aromatic C), 136.7 (C, 
aromatic C), 166.3 (C=O), 166.5 (C=O), 174.5 (COOH); m/z 
(ESI+) 457.3 [(M+H)+ 100%]; HRMS (ESI+): Exact mass 
calculated for (C27H25N2O5)+ 457.1763. Found 457.1755. 
 
Substitutions on isopropyl intermediate  
3-(1-Isopropyl-1H-indol-3-yl)-4-(1-methyl-1H-indol-3-
yl)furan-2,5-dione 45  
To a solution of 3-(1H-indol-3-yl)-4-(1-isopropyl-1H-indol-3-
yl)furan-2,5-dione 40 (0.302 g, 0.81 mmol) in anhydrous DMF 
(15 mL) under nitrogen was added sodium hydride (60 wt. % oil 
dispersion, 0.037 g, 1.5 mmol) and the mixture was stirred for 40 
minutes at room temperature. Iodomethane (0.06 mL, 0.14 g, 
0.97 mmol) was then added and the reaction was allowed to stir 
for a further 16 hours. Water (30 mL) was then added and the 
mixture was extracted with ethyl acetate (3 × 20 mL). The 
combined organic layers were then washed with 1 M aqueous 
HCl (2 × 20 mL), followed by water (20 mL) and brine (20 mL) 
before being dried over anhydrous magnesium sulfate, filtered 
and the solvent evaporated under reduced pressure. The crude 
residue was purified using column chromatography on silica gel 
with 20% ethyl acetate/hexane to give desired product as a red 
solid (0.140 g, 46%): m.p. 164-167 °C; νmax/cm-1 (KBr) 3118, 
3048, 2970, 1812, 1745, 1627, 1529, 1247, 739; δH (300 MHz, 
DMSO-d6) 1.37 [6H, d, J 6.7, 2 × CH3], 3.90 (3H, s, CH3), 4.81 
[1H, sept, J 6.6, CH(CH3)2], 6.60 [1H, d, J 8.0, C(7)-H], 6.72 
[1H, t, J 8.0, C(6)-H], 6.87 [1H, t, J 7.8, C(6′)-H], 7.09-7.19 [3H, 
m, C(5, 5′, 7′)-H], 7.50 [1H, d, J 8.4, C(4)-H], 7.59 [1H, d, J 8.4, 
C(4′)-H], 7.73 [1H, s, C(2′)-H], 8.01 [1H, s, C(2)-H]; δc (75 
MHz, DMSO-d6) 22.0 (2 × CH3), 33.0 [CH(CH3)2], 47.2 (CH3), 
103. 9 (C, aromatic C), 104.5 (C, aromatic C), 110.5 (CH, 
aromatic CH), 110.6 (CH, aromatic CH), 120.1 (CH, aromatic 
CH), 120.2 (CH, aromatic CH), 121.5 (CH, aromatic CH), 121.6 
(CH, aromatic CH), 122.15 (CH, aromatic CH), 122.18 (CH, 
aromatic CH), 124.5 (C, aromatic C), 125.7 (C, aromatic C), 
126.9 (C, aromatic C), 128.1 (C, aromatic C), 129.1 (CH, 
aromatic CH), 134.65 (CH, aromatic CH), 134.69 (C, aromatic 
C), 136.9 (C, aromatic C), 166.2 (C=O), 166.5 (C=O); m/z (ESI+) 
385.3 [(M+H)+, 100%]; HRMS (ESI+): Exact mass calculated for 
(C24H21N2O3)+ 385.1552. Found 385.1540. 
3-(1-Ethyl-1H-indol-3-yl)-4-(1-isopropyl-1H-indol-3-yl)furan-
2,5-dione 46 
To a solution of 3-(1H-indol-3-yl)-4-(1-isopropyl-1H-indol-3-
yl)furan-2,5-dione 40 (0.167 g, 0.45 mmol) in anhydrous DMF 
(10 mL) under nitrogen was added sodium hydride (60 wt. % oil 
dispersion, 0.019 g, 0.83 mmol) and the mixture was stirred for 
40 minutes at room temperature. Iodoethane (0.06 mL, 0.12 g, 
0.69 mmol) was then added and the reaction was allowed to stir 
for a further 16 hours. Water (20 mL) was then added and the 
mixture was extracted with ethyl acetate (3 × 15 mL). The 
combined organic layers were then washed with 1 M aqueous 
HCl (2 × 15 mL), followed by water (15 mL) and brine (15 mL) 
before being dried over anhydrous magnesium sulfate, filtered 
and the solvent evaporated under reduced pressure. The crude 
residue was purified using column chromatography on silica gel 
with 20% ethyl acetate/hexane to give desired product as an 
orange solid (0.091 g, 51%): m.p. 165-167 °C; νmax/cm-1 (KBr) 
2978, 1817, 1746, 1524, 1211, 741; δH (400 MHz, DMSO-d6) 
1.34 (3H, t, J 7.1, CH2CH3) 1.40 [6H, d, J 6.7, 2 × CH3], 4.30 
(2H, q, J 7.2, CH2CH3), 4.82 [1H, sept, J 6.6 CH(CH3)2], 6.75-
6.86 [3H, m, C(6, 6′, 7)-H), 7.04 [1H, d, J 7.7, C(7′)-H] 7.10-7.16 
[2H, m, C(5, 5′)-H), 7.56 [1H, d, J 8.1, C(4)-H], 7.60 [1H, d, J 
8.3, C(4′)-H], 7.80 [1H, s, C(2′)-H], 7.93 [1H, s, C(2)-H]; δc (75 
MHz, DMSO-d6) 15.1 (CH3), 22.1 (2 × CH3), 40.9 (CH2), 47.2 
(CH), 104.1 (C, aromatic C), 104.4 (C, aromatic C), 110.5 (CH, 
aromatic CH), 110.7 (CH, aromatic CH), 120.1 (CH, aromatic 
CH), 120.2 (CH, aromatic CH), 121.65 (CH, aromatic CH), 
121.73 (CH, aromatic CH), 122.1 (CH, aromatic CH), 122.2 
(CH, aromatic CH), 125.0 (C, aromatic C), 125.3 (C, aromatic 
C), 127.4 (C, aromatic C), 127.9 (C, aromatic C), 129.3 (CH, 
aromatic CH), 132.9 (CH, aromatic CH), 135.5 (C, aromatic C), 
135.8 (C, aromatic C), 166.3 (C=O), 166.4 (C=O); m/z (ESI+) 
399.3 [(M+H)+, 100%]; HRMS (ESI+): Exact mass calculated for 
(C25H23N2O3)+ 399.1709. Found 399.1706. 
 
Synthesis of bisindolyl hydroxymaleimides 
General procedure (i): To a solution of maleic anhydride (1 eq.) 
in anhydrous DMF (30 mL/mmol) was added hydroxylamine 
hydrochloride (5 eq.) followed by triethylamine (5 eq.). The 
mixture was then heated to 70 °C and stirred at this temperature 
for 24 hours. After cooling, water (100 mL/mmol) was added and 
the mixture was extracted with ethyl acetate (3 × 40 mL/mmol). 
The organic layer was washed with 1 M aqueous HCl (2 × 50 
mL/mmol), followed by water (50 mL/mmol) and brine (50 
mL/mmol) before being dried over anhydrous magnesium 




Following general procedure (i) starting from 3-(1H-indol-3-yl)-
4-(1-methyl-1H-indol-3-yl)furan-2,5-dione 39 (0.104 g, 0.29 
mmol) in anhydrous DMF (8 mL) with hydroxylamine 
hydrochloride (0.101 g, 1.5 mmol) and triethylamine (0.20 mL, 
0.15 g, 1.5 mmol) gave desired product as a dark red solid (83%): 
m.p. 137-139 °C; νmax/cm-1 (KBr) 3332, 2930, 1767, 1706, 1612, 
1529, 1460, 1023; δH (300 MHz, DMSO-d6) 3.87 (3H, s, CH3), 
6.61-6.74 [3H, m, C(6, 6′, 7′)-H], 6.83 [1H, d, J 8.0, C(7)-H], 
6.99 [1H, t, J 7.5, C(5)-H], 7.04 [1H, t, J 7.5, C(5′)-H], 7.39 [1H, 
d, J 8.0, C(4)-H], 7.44 [1H, d, J 8.1, C(4′)-H], 7.77 [1H, d, J 7.8, 
C(2)-H], 7.87 [1H, s, C(2′)-H], 10.45 (1H, s, N-OH), 11.74 (1H, 
bs, NH); δc (75 MHz, DMSO-d6)  32.9 (CH3), 104.5 (C, aromatic 
C), 105.5 (C, aromatic C), 110.2 (CH, aromatic CH), 111.9 (CH, 
aromatic CH), 119.4 (CH, aromatic CH), 119.7 (CH, aromatic 
CH), 120.8 (CH, aromatic CH), 121.0 (CH, aromatic CH), 121.7 
(CH, aromatic CH), 121.8 (CH, aromatic CH), 123.9 (C, 
aromatic C), 124.0 (C, aromatic C), 125.4 (C, aromatic C), 125.6 
(C, aromatic C), 129.3 (CH, aromatic CH), 133.2 (CH, aromatic 
CH), 135.9 (C, aromatic C), 136.5 (C, aromatic C), 168.5 (2 × 
C=O); m/z (ESI-) 356.2 [(M-H)- 50%]. HRMS (ESI-): Exact mass 
calculated for (C21H14N3O3)- 356.1035. Found 356.1025.  
1-Hydroxy-3,4-bis(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-
dione 48 
Following general procedure (i) starting from 3,4-bis(1-methyl-
1H-indol-3-yl)furan-2,5-dione 41 (0.092 g, 0.26 mmol) in 
anhydrous DMF (10 mL) with hydroxylamine hydrochloride 
(0.090 g, 1.3 mmol) and triethylamine (0.18 mL, 0.13 g, 1.3 
mmol) gave desired product as a dark red solid (0.081 g, 84%): 
m.p. >300 °C; νmax/cm-1 (KBr) 3224, 1764, 1694, 1610, 1519, 
1367, 1097; δH (300 MHz, DMSO-d6) 3.86 (6H, s, 2 × CH3), 6.67 
[2H, t, J 7.4, C(6, 6′)-H], 6.76 [2H, d, J 7.9, C(7, 7′)-H], 7.05 
[2H, t, J 7.4, C(5, 5′)-H], 7.44 [2H, d, J 8.2, C(4, 4′)-H], 7.84 
(2H, s, C(2, 2′)-H], 10.44 (1 H, s, N-OH); δc (75 MHz, DMSO-
d6)  32.9 (2 × CH3), 104.6 (2C, 2 × aromatic C), 110.2 (2CH, 2 × 
aromatic CH), 119.6 (2CH, 2 × aromatic CH), 121.1 (2CH, 2 × 
aromatic CH), 121.8 (2CH, 2 × aromatic CH), 123.7 (2C, 2 × 
aromatic C), 125.7 (2C, 2 × aromatic C), 133.2 (2CH, 2 × 
aromatic CH), 136.5 (2C, 2 × aromatic C), 168.4 (2 × C=O); m/z 
(ESI+) 372.1 [(M+H)+ 100%]. HRMS (ESI+): Exact mass 
calculated for (C22H18N3O3)+ 372.1348. Found 372.1348. 
3-(1-Ethyl-1H-indol-3-yl)-1-hydroxy-4-(1-methyl-1H-indol-3-
yl)-1H-pyrrole-2,5-dione 49 
Following general procedure (i) starting from 3-(1-ethyl-1H-
indol-3-yl)-4-(1-methyl-1H-indol-3-yl)furan-2,5-dione 42 (0.103 
g, 0.27 mmol) in anhydrous DMF (10 mL) with hydroxylamine 
hydrochloride (0.094 g, 1.3 mmol) and triethylamine (0.2 mL, 
0.14 g, 1.3 mmol) gave desired product as a dark red solid (0.072 
g, 69%): m.p. = 236-238 °C; νmax/cm-1 (KBr) 3239, 2932, 1763, 
1699, 1523, 1219, 739; δH (300 MHz, DMSO-d6) 1.30 (3H, t, J 
7.6, CH2CH3), 3.87 (3H, s, CH3), 4.24 (2H, q, J 7.1 CH2CH3), 
6.62-6.69 [2H, m, C(6′, 7′)-H], 6.75 [1H, t, J 7.6, C(6)-H], 6.96 
[1H, d, J 8.15, C(7)-H], 7.03-7.11 [2H, m, (5, 5′)-H], 7.45 [1H, d, 
J 8.15, C(4′)-H], 7.50 [1H, d, 8.49, C(4)-H], 7.74 [1H, s, C(2)-H], 
7.90 [1H, s, C(2′)-H], 10.47 (N-OH); δc (75 MHz, DMSO-d6)  
15.2 (CH2CH3), 32.9 (CH3), 40.7 (CH2CH3), 104.4 (C, aromatic 
C), 104.8 (C, aromatic C), 110.18 (CH, aromatic CH), 110.23 
(CH, aromatic CH), 119.65 (CH, aromatic CH), 119.67 (CH, 
aromatic CH), 121.2 (CH, aromatic CH), 121.3 (CH, aromatic 
CH), 121.8 (2CH, 2 × aromatic CH), 123.4 (C, aromatic C), 
124.1 (C, aromatic C), 125.2 (C, aromatic C), 126.0 (C, aromatic 
C), 131.6 (CH, aromatic CH), 133.4 (CH, aromatic CH), 135.4 
(C, aromatic C), 136.6 (C, aromatic C), 168.37 (C=O), 168.41 
(C=O); m/z (ESI+) 386.2 [(M+H)+ 100%]. HRMS (ESI+): Exact 
mass calculated for (C23H20N3O3)+ 386.1505. Found 386.1509. 
6-{3-[1-Hydroxy-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-
dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}hexanenitrile 50 
Following general procedure (i) starting from 6-(3-(4-(1-
methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl)-1H-
indol-1-yl)hexanenitrile 43 (0.103 g, 0.235 mmol) in anhydrous 
DMF (8 mL) with hydroxylamine hydrochloride (0.079 g, 1.18 
mmol) and triethylamine (0.16 mL, 0.12 g, 1.2 mmol) gave 
desired product as a dark red solid (0.087 g, 82%): m.p. 123-
125 °C; νmax/cm-1(KBr) 3229, 2935, 2244, 1769, 1708, 1529, 
1099, 742; δH (300 MHz, DMSO-d6) 1.22-1.39 [2H, m, C(4′′)-
H2], 1.57 [2H, quin, J 7.27, C(3′′)- H2], 1.73 [2H, quin, J 7.04, 
C(5′′)-H2], 2.45 [2H, t, J 7.2, C(2′′)-H2], 3.88 (3H, s, CH3), 
4.23 [2H, t, J 6.9, C(6′′)-H2], 6.62-6.68 [2H, m, C(6′, 7′)-H], 
6.73 [1H, t, J 7.7, C(6)-H], 6.94 [1H, d, J 7.8, C(7)-H], 7.01-
7.10 [2H, m, (5, 5′)-H], 7.45 [1H, d, J 8.0, C(4′)-H], 7.50 [1H, 
d, J 8.2, C(4)-H], 7.75 [1H, s, C(2)-H], 7.90 [1H, s, C(2′)-H], 
10.43 (1H, s, NOH); δc (75 MHz, DMSO-d6) 16.0 (CH2), 24.3 
(CH2), 25.2 (CH2), 28.8 (CH2), 32.9 (CH3), 45.9 (CH2), 104.4 
(C, aromatic C), 104.9 (C, aromatic C), 110.2 (CH, aromatic 
CH), 110.3 (CH, aromatic CH), 119.6 (2 × CH, 2 aromatic CH), 
120.6 (CN), 121.1 (CH, aromatic CH), 121.2 (CH, aromatic 
CH), 121.77 (CH, aromatic CH), 121.81 (CH, aromatic CH), 
123.5 (C, aromatic C), 124.2 (C, aromatic C), 125.3 (C, 
aromatic C), 126.0 (C, aromatic C), 132.0 (CH, aromatic CH), 
133.3 (CH, aromatic CH), 135.7 (C, aromatic C), 136.6 (C, 
aromatic C), 168.3 (C=O), 168.4 (C=O); m/z (ESI-) 451.3 [(M-
H)- 50%]; HRMS (ESI-): Exact mass calculated for 
(C27H23N4O3)- 451.1770. Found 451.1783. 
6-{3-[1-Hydroxy-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-
dihydro-1H-pyrrol-3-yl]-1H-indol-1-yl}hexanoic acid 51 
Following general procedure (i) starting from 6-{3-[4-(1-
methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl]-1H -
indol-1-yl}hexanoic acid 44 (0.101 g, 0.221 mmol) in 
anhydrous DMF (8 mL) with hydroxylamine hydrochloride 
(0.076 g, 1.11 mmol) and triethylamine (0.15 mL, 0.11 g, 1.1 
mmol) gave desired compound as a dark red solid (0.085 g, 
79%): m.p. 196-197 °C; νmax/cm-1 (KBr) 3114, 2935, 1710, 
1609, 1529, 1098, 741; δH (300 MHz, DMSO-d6) 1.16-1.29 
[2H, m, C(4′′)-H2], 1.51 [2H, quin, J 7.4, C(3′′)-H2], 1.70 [2H, 
quin, J 7.1, C(5′′)-H2], 2.17 [2H, t, 7.3, C(2′′)-H2], 3.87 (3H, s, 
CH3), 4.21 [2H, t, J 6.7, C(6′′)-H2], 6.58-6.66 [2H, m, C(6′, 7′)-
H], 6.72 [1H, t, J 7.4, C(6)-H], 6.93 [1H, d, J 8.0, C(7)-H], 
7.00-7.09 [2H, m, (5, 5′)-H], 7.43 [1H, d, J 8.3, C(4′)-H], 7.48 
[1H, d, J 8.3, C(4)-H], 7.73 [1H, s, C(2)-H], 7.90 [1H, s, C(2′)-
H], 10.43 (1H, bs, NH), 11.99 (1H, bs, COOH); δc (75 MHz, 
DMSO-d6) 24.0 (CH2), 25.6 (CH2), 29.3 (CH2), 32.9 (CH3), 
33.5 (CH2), 45.6 (CH2), 104.4 (C, aromatic C), 104.8 (C, 
aromatic C), 110.17 (CH, aromatic CH), 110.24 (CH, aromatic 
CH), 119.57 (CH, aromatic CH), 119.59 (CH, aromatic CH), 
121.10 (CH, aromatic CH), 121.12 (CH, aromatic CH), 121.8 
(2CH, 2 × aromatic CH), 123.5 (C, aromatic C), 124.3 (C, 
aromatic C), 125.3 (C, aromatic C), 126.0 (C, aromatic C), 
132.0 (CH, aromatic CH), 133.3 (CH, aromatic CH), 135.7 (C, 
aromatic C), 136.6 (C, aromatic C), 168.4 (C=O), 168.4 (C=O), 
174.3 (COOH); m/z (ESI+) 472.2 [(M+H)+ 100%]; HRMS 




Following general procedure (i) starting from 3-(1H-indol-3-yl)-
4-(1-isopropyl-1H-indol-3-yl)furan-2,5-dione 40 (0.120 g, 0.31 
mmol) in anhydrous DMF (8 mL) with hydroxylamine 
hydrochloride (0.11 g, 1.6 mmol) and triethylamine (0.23 mL, 
0.17 g, 1.6 mmol) gave desired product as a dark red solid (0.097 
g, 77%): m.p. 106-109 °C; νmax/cm-1 (KBr) 3118, 3135, 2970, 
1812, 1745, 1627, 1529, 1247; δH (300 MHz, DMSO-d6) 1.38 
(6H, d, J 6.6, 2 × CH3), 4.78 [1H, sept, J 6.7 CH(CH3)2], 6.63 
(2H, m, C(6, 7)-H], 6.78 [1H, t, J 7.2, C(6′)-H], 6.96-7.10 [3H, 
m, C(5, 5′, 7′)-H], 7.39 [1H, d, J 8.1, C(4)-H], 7.53 [1H, d, J 8.3, 
C(4′)-H], 7.69 [1H, s, C(2′)-H], 7.83 [1H, d, J 2.8, C(2)-H], 10.42 
(1H, s, N-OH), 11.74 (1H, s, N-H); δc (75 MHz, DMSO-d6) 22.1 
[CH(CH3)2], 47.0 [CH(CH3)2], 105.0 (C, aromatic C), 105.2 (C, 
aromatic C), 110.3 (CH, aromatic CH), 111.9 (CH, aromatic 
CH), 119.5 (CH, aromatic CH), 119.8 (CH, aromatic CH), 121.1 
(CH, aromatic CH), 121.3 (CH, aromatic CH), 121.71 (CH, 
aromatic CH), 121.73 (CH, aromatic CH), 123.6 (C, aromatic C), 
124.6 (C, aromatic C), 124.9 (C, aromatic C), 125.9 (C, aromatic 
C), 128.2 (CH, aromatic CH), 129.8 (CH, aromatic CH), 135.3 
(C, aromatic C), 136.1 (C, aromatic C), 168.37 (C=O), 168.44 
(C=O); m/z (ESI+) 386.4 [(M+H)+, 100%]; HRMS (ESI+): Exact 
mass calculated for (C23H20N3O3)+ 386.1505. Found 386.1495. 
1-Hydroxy-3-(1-isopropyl-1H-indol-3-yl)-4-(1-methyl-1H-
Indol-3-yl)-1H-pyrrole-2,5-dione 53 
Following general procedure (i) starting from 3-(1-isopropyl-1H-
indol-3-yl)-4-(1-methyl-1H-indol-3-yl)furan-2,5-dione 45 (0.099 
g, 0.26 mmol) in anhydrous DMF (8 mL) with hydroxylamine 
hydrochloride (0.089 g, 1.29 mmol) and triethylamine (0.18 mL, 
0.13 g, 1.29 mmol) gave desired product as a dark red solid 
(0.096 g, 93%): m.p. 84-86 °C; νmax/cm-1 (KBr) 3118, 2930, 1712, 
1654; δH (300 MHz, DMSO-d6) 1.37 (6H, d, J 6.6, 2 × CH3), 4.78 
[1H, sept, J  6.6, CH(CH3) 2], 6.52 [1H, d, J 7.7, C(7)-H] 6.63 
[1H, t, J 7.2, C(6)-H], 6.80 [1H, t, J 7.3, C(6′)-H], 7.03-7.11 [3H, 
m, C(5, 5′, 7)-H], 7.45 [1H, d, J 8.2, C(4)-H], 7.54 [1H, d, J 8.5, 
C(4′)-H], 7.67 [1H, s, C(2′)-H], 7.93 [1H, s, C(2)-H], 10.48 (1H, 
s, N-OH); δc (75 MHz, DMSO-d6)  22.1 (2 × CH3), 32.9 
[CH(CH3)2], 47.0 (CH3), 104.3 (C, aromatic C), 105.1 (C, 
aromatic C), 110.2 (CH, aromatic CH), 110.3 (CH, aromatic 
CH), 119.7 (CH, aromatic CH), 119.8 (CH, aromatic CH), 121.3 
(2CH, 2 × aromatic CH), 121.75 (CH, aromatic CH), 121.77 
(CH, aromatic CH), 123.4 (C, aromatic C), 124.6 (C, aromatic 
C), 124.9 (C, aromatic C), 126.0 (C, aromatic C), 128.2 (CH, 
aromatic CH), 133.6 (CH, aromatic CH), 135.3 (C, aromatic C), 
136.7 (C, aromatic C), 168.3 (C=O), 168.4 (C=O); m/z (ESI+) 
400.2 [(M+H)+, 100%]; HRMS (ESI+): Exact mass calculated for 
(C24H22N3O3)+ 400.1661. Found 400.1651. 
3-(1-Ethyl-1H-indol-3-yl)-1-hydroxy-4-(1-isopropyl-1H-indol-
3-yl)-1H-pyrrole-2,5-dione 54 
Following general procedure (i) starting from 3-(1-ethyl-1H-
indol-3-yl)-4-(1-isopropyl-1H-indol-3-yl)furan-2,5-dione 46 
(0.068 g, 0.17 mmol) in anhydrous DMF (8 mL) with 
hydroxylamine hydrochloride (0.059 g, 0.85 mmol) and 
triethylamine (0.12 mL, 0.87 g, 0.85 mmol) gave desired product 
as a dark red solid (0.056 g, 80%): m.p. 83-85 °C; νmax/cm-1 
(KBr) 3125, 2975, 1769, 1713, 1527, 1214, 741; δH (300 MHz, 
DMSO-d6,) 1.34 (3H, t, J 7.2, CH2CH3) 1.39 (6H, d, J 6.6, 2 × 
CH3), 4.27 (2H, q, J 7.2, CH2CH3), 4.79 [1H, sept, J 6.6 
CH(CH3)2], 6.66-6.72 [2H, m, C(6, 7)-H], 6.76 [1H, t, J 7.6, 
C(6′)-H], 6.95 [1H, d, J 7.8, C(7′)-H], 7.04-7.11 [2H, m, C(5, 5′)-
H], 7.50 [1H, d, J 8.3, C(4)-H], 7.55 [1H, d, J 8.4, C(4′)-H], 7.74 
[1H, s, C(2′)-H], 7.85 [1H, s, C(2)-H], 10.47 (1H, s, N-OH), δc 
(75 MHz, DMSO-d6) 15.2 (CH3), 22.1 (2 × CH3), 40.7 (CH2), 
47.0 (CH), 104.6 (C, aromatic C), 105.0 (C, aromatic C), 110.2 
(CH, aromatic CH), 110.4 (CH, aromatic CH), 119.7 (CH, 
aromatic CH), 119.8 (CH, aromatic CH), 121.38 (CH, aromatic 
CH), 121.44 (CH, aromatic CH), 121.7 (CH, aromatic CH), 
121.8 (CH, aromatic CH), 123.9 (C, aromatic C), 124.3 (C, 
aromatic C), 125.3 (C, aromatic C), 125.7 (C, aromatic C), 128.4 
(CH, aromatic CH), 131.9 (CH, aromatic CH), 135.4 (C, 
aromatic C), 135.6 (C, aromatic C), 168.3 (C=O), 168.4 (C=O); 
m/z (ESI+) 414.2 [(M+H)+, 100%]; HRMS (ESI+): Exact mass 




Following general procedure (i) starting from 6,7,8,9,10,11-
hexahydro-5,21:12,17-dimethenodibenzo[i,o]furo[3,4-
l][1,8]diazacyclohexadecine-18,20-dione 27 (0.151 g, 0.37 
mmol) in anhydrous DMF (10 mL) with hydroxylamine 
hydrochloride (0.127 g, 1.8 mmol) and triethylamine (0.26 mL, 
0.19 g, 1.8 mmol) gave desired product as a purple solid (0.129 
g, 82%): m.p. >300 °C; νmax/cm-1 (KBr) 3373, 2924, 1768, 1712, 
1619, 1534, 1470, 1390, 735; δH (300 MHz, DMSO-d6) 1.06 [4H, 
bs, C(8, 9)-H2], 1.80 [4H, bs, C(7, 10)-H2], 4.12-4.22 [4H, m, 
C(6, 11)-H2], 7.14 [2H, ddd, J 7.9, 7.2, 1.0, C(2, 15)-H], 7.21 
[2H, ddd, J 8.2, 7.1, 1.2, C(3, 14)-H], 7.39 [2H, s, C(22, 23)-H], 
7.51 [2H, d, J 7.8, C(4, 13)-H], 7.81 [2H, dd, J 7.1, 0.9, C(1, 16)-
H], 10.47 (N-OH); δc (75 MHz, DMSO-d6)  22.7 (2 × CH2), 27.3 
(2 × CH2), 44.2 (2 × CH2), 102.5 (2C, 2 × aromatic C), 110.5 
(2CH, 2 × aromatic CH), 120.2 (2CH, 2 × aromatic CH), 121.4 
(2CH, 2 × aromatic CH), 121.7 (2CH, 2 × aromatic CH), 126.8 
(2C, 2 × aromatic C), 128.6 (2C, 2 × aromatic C), 131.9 (2CH, 2 
× aromatic CH), 135.2 (2C, 2 × aromatic C), 167.7 (2 × C=O); 
m/z (ESI+) 426.2 [(M+H)+ 10%]; HRMS (ESI+): Exact mass 
calculated for (C26H24N3O3)+ 426.1818. Found 426.1827. 
6,6'-[3,3'-(1-Hydroxy-2,5-dioxo-2,5-dihydro-1H-pyrrole-3,4-
diyl)bis(1H-indole-3,1-diyl)]dihexanenitrile 56 
Following general procedure (i) starting from 6,6'-[3,3'-(2,5-
dioxo-2,5-dihydrofuran-3,4-diyl)bis(1H-indole-3,1-
diyl)]dihexanenitrile 28 (0.084g, 0.162 mmol) in anhydrous 
DMF (8 mL) with hydroxylamine hydrochloride (0.056 g, 0.809 
mmol) and triethylamine (0.11 mL, 0.08 g, 0.81 mmol) gave 
desired product as a dark red solid (0.076 g, 87%): m.p. 83-84 
°C; νmax/cm-1 (KBr) 3257, 2936, 2244, 1771, 1713, 1530, 1392, 
1159, 743; δH (300 MHz, DMSO-d6) 1.25-1.38 [4H, m, 2 × 
C(4′′)-H2], 1.57 [4H, quin, J 7.4, 2 × C(3′′)-H2], 1.75 [4H, quin, 
J 7.2, 2 × C(5′′)-H2], 2.45 [4H, t, J 7.1, 2 × C(2′′)-H2], 4.25 
[4H, t, J 6.9, × C(6′′)-H2], 6.68 [2H, t, J 7.4, C(6, 6′)-H], 6.80 
[2H, d, J 7.7, C(7, 7′)-H], 7.05 [2H, t, J 7.6, C(5, 5′)-H], 7.50 
[2H, d, J 8.3, C(4, 4′)-H], 7.82 [2H, s, C(2, 2′)-H], 10.43 (N-
OH); δc (75 MHz, DMSO-d6) 16.0 (2 × CH2), 24.3 (2 × CH2), 
25.2 (2 × CH2), 28.7 (2 × CH2), 45.4 (2 × CH2), 104.7 (2C, 2 × 
aromatic C), 110.3 (2CH, 2 × aromatic CH), 119.6 (2CH, 2 × 
aromatic CH), 120.5 (2 × CN), 121.2 (2CH, 2 × aromatic CH), 
121.8 (2CH, 2 × aromatic CH), 124.0 (2C, 2 × aromatic C), 
125.6 (2C, 2 × aromatic C), 132.1 (2CH, 2 × aromatic CH), 
135.8 (2C, 2 × aromatic C), 168.3 (2 × C=O); m/z (ESI+) 534.3 
[(M+H)+ 40%]; HRMS (ESI+): Exact mass calculated for 
(C32H32N5O3)+ 534.2505. Found 534.2496. 
6-{3-[1-Hydroxy-4-(1H-indol-3-yl)-2,5-dioxo-2,5-dihydro-
1H-pyrrol-3-yl]-1Hindol-1-yl}hexanoic acid 57 
Following general procedure (i) starting from 6-{3-[4-(1Hindol-
3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl]-1H-indol-1-yl}hexanoic 
acid 30 (0.120 g, 0.271 mmol) in anhydrous DMF (10 mL) with 
hydroxylamine hydrochloride (0.094 g, 1.36 mmol) and 
triethylamine (0.19 mL, 0.14 g, 1.4 mmol) gave desired product 
as a dark red solid (0.107 g, 86%): m.p. 133-135 °C; νmax/cm-1 
(KBr) 3372, 2935, 1768, 1703, 1612, 1527, 1391, 1097, 735; 
δH (400 MHz, DMSO-d6) 1.18-1.27 [2H, m, C(4′′)-H2], 1.51 
[2H, quin, J 7.5, C(3′′)-H2], 1.71 [2H, quin, J 7.3, C(5′′)-H2], 
2.18 [2H, t, J 7.4, C(2′′)-H], 4.22 [2H, t, J 6.9, C(6′′)-H], 6.60 
[1H, t, J 7.6, C(6)-H], 6.67-6.73 [2H, m, C(6′, 7)-H], 6.87 [1H, 
d, J 8.2, C(7′)-H], 6.98 [1H, t, J 7.6, C(5)-H], 7.04 [1H, t, J 7.7, 
C(5′)-H], 7.38 [1H, d, J 8.2, C(4)-H], 7.48 [1H, d, J 8.3, C(4′)-
H], 7.77 [1H, s, C(2′)-H], 7.82 [1H, d, J 2.9, C(2)-H], 10.45 
(1H, s, NOH), 11.75 (1H, bd, J 2.4, NH), 12.02 (1H, bs, 
COOH); δc (75 MHz, DMSO-d6) 24.0 (CH2), 25.6 (CH2), 29.3 
(CH2), 33.5 (CH2), 45.6 (CH2), 104.7 (C, aromatic C), 105.4 (C, 
aromatic C), 110.2 (CH, aromatic CH), 111.8 (CH, aromatic 
CH), 119.4 (CH, aromatic CH), 119.6 (CH, aromatic CH), 
120.9 (CH, aromatic CH), 121.1 (CH, aromatic CH), 121.7 
(CH, aromatic CH), 121.8 (CH, aromatic CH), 123.8 (C, 
aromatic C), 124.6 (C, aromatic C), 125.0 (C, aromatic C), 
125.9 (C, aromatic C), 129.5 (CH, aromatic CH), 132.0 (CH, 
aromatic CH), 135.8 (C, aromatic C), 136.0 (C, aromatic C), 
168.39 (C=O), 168.44 (C=O), 174.3 (COOH); m/z (ESI+) 458.2 
[(M+H)+ 100%]; HRMS (ESI+): Exact mass calculated for 
(C26H24N3O5)+ 458.1716. Found 458.1700. 
6,6'-[3,3'-(2,5-Dioxo-2,5-dihydro-1H-pyrrole-3,4-
diyl)bis(1H-indole-3,1-diyl)]dihexanenitrile 58 
To a solution of 6,6'-[3,3'-(2,5-dioxo-2,5-dihydrofuran-3,4- 
diyl)bis(1H-indole-3,1-diyl)]dihexanenitrile 28 (1.302 g, 2.51 
mmol) in anhydrous DMF (10 mL) was added 1,1,1,3,3,3 
hexamethyldisilazane (3.53 mL, 0.77 g, 28.4 mmol), followed 
by methanol (0.34 mL, 0.27 g, 8.4 mmol) and the reaction 
mixture was stirred at room temperature for 8 hours. Water (40 
mL) was then added and the product extracted into ethyl acetate 
(3 × 30 mL). The combined organic layers were washed with 
water (3 × 40 mL) followed by brine (40 mL) before being 
dried over anhydrous magnesium sulfate, filtered and the 
solvent evaporated under reduced pressure to give a red solid 
(1.165 g, 90%): m.p. 82-84 °C; νmax/cm-1 (KBr) 3274, 2936, 
2244, 1704, 1533, 1334, 1160, 743; δH  (300 MHz, CDCl3) 
1.39-1.51 [4H, m, 2 × C(4′′)-H2], 1.65 [4H, quin, J 7.3, 2 × 
C(3′′)-H2], 1.87 [4H, quin, J 7.3, 2 × C(5′′)-H2], 2.30 [4H, t, J 
7.0, 2 × C(2′′)-H2], 4.15 [4H, t, J 7.0, 2 × C(6′′)-H2],  6.76 [2H, 
t, J 7.4, C(6, 6′)-H], 6.99 [2H, d, J 8.0, C(7, 7′)- H], 7.11 [2H, t, 
J 7.6, C(5, 5′)-H], 7.28 [2H, d, J 8.3, C(4, 4′)-H], 7.43 (1H, s, 
NH), 7.63 [1H, s, C(2, 2′)-H]; δc  (75 MHz, CDCl3)  17.0 (2 × 
CH2), 25.0 (2 × CH2), 25.9 (2 × CH2), 29.2 (2 × CH2), 46.3 (2 × 
CH2), 105.9 (2C, 2 × aromatic C), 109.5 (2CH, 2 × aromatic 
CH), 119.4 (2 × CN), 120.1 (2CH, 2 × aromatic CH), 122.3 
(2CH, 2 × aromatic CH), 122.4 (2CH, 2 × aromatic CH), 126.2 
(2C, 2 × aromatic C), 127.8 (2C, 2 × aromatic C), 131.7 (2CH, 
2 × aromatic CH), 136.2 (2C, 2 × aromatic C), 172.3 (2 × 
C=O); m/z (ESI+) 518.2 [(M+H)+ 100%]; HRMS (ESI+): 
Exact mass calculated for (C32H32N5O2)+ 518.2556. Found 
518.2554. 
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15 >10 >10 >10 0.10 0.80 0.08 >10 0.03 2.0 >10 
22 >10 >10 >10 >10 >10 >10 >10 4.0 4.5 >10 
47 >10 >10 >10 >10 >10 2.0 >10 0.20 5.0 >10 
48 >10 >10 >10 >10 >10 9.0 >10 3.0 >10 >10 
49 >10 >10 >10 >10 >10 1.5 >10 0.30 >10 >10 
50 >10 >10 >10 >10 >10 2.10 5.00 0.27 >10 >10 
51 >10 >10 >10 4.0 >10 0.70 1.00 3.20 >10 >10 
52 >10 >10 >10 >10 >10 >10 >10 1.5 >10 >10 
53 >10 >10 >10 7.0 >10 1.5 >10 0.20 >10 >10 
54 >10 >10 >10 >10 >10 0.70 >10 0.40 >10 >10 
55 >10 >10 >10 >10 >10 >10 >10 >10 >10 >10 
56 >10 >10 >10 >10 >10 >10 >10 0.75 >10 >10 
57 >10 >10 >10 >10 >10 2.00 2.00 0.75 >10 >10 
58 >10 >10 >10 2.50 >10 0.42 0.62 0.12 >10 >10 
 
Table 2 IC50 values from the kinase inhibition assay (values quoted in µM) 
